SEARCH

SEARCH BY CITATION

Keywords:

  • diagnosis;
  • epidemiology;
  • HCV;
  • hepatitis C;
  • incidence;
  • mortality;
  • prevalence

Abstract

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Background and Aim: Decisions on public health issues are dependent on reliable epidemiological data. A comprehensive review of the literature was used to gather country-specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution of the hepatitis C virus (HCV) infection in selected European countries, Canada and Israel.

Methodology: Data references were identified through indexed journals and non-indexed sources. In this work, 13 000 articles were reviewed and 860 were selected based on their relevance.

Results: Differences in prevalence were explained by local and regional variances in transmission routes or different public health measures. The lowest HCV prevalence (≤0.5%) estimates were from northern European countries and the highest (≥3%) were from Romania and rural areas in Greece, Italy and Russia. The main risk for HCV transmission in countries with well-established HCV screening programmes and lower HCV prevalence was injection drug use, which was associated with younger age at the time of infection and a higher infection rate among males. In other regions, contaminated glass syringes and nosocomial infections continue to play an important role in new infections. Immigration from endemic countries was another factor impacting the total number of infections and the genotype distribution. Approximately 70% of cases in Israel, 37% in Germany and 33% in Switzerland were not born in the country. In summary, HCV epidemiology shows a high variability across Europe, Canada and Israel.

Conclusion: Despite the eradication of transmission by blood products, HCV infection continues to be one of the leading blood-borne infections in the region.

Abbreviations
CHC,

chronic hepatitis C;

CHS,

Clalit Health Services;

ECDC,

European Center for Disease Prevention and Control;

EEG,

electroencephalogram;

EHSSS,

The Enhanced Hepatitis Strain Surveillance System of Canada;

EMCDDA,

European Monitoring Centre for Drugs and Drug Addiction;

EU,

European Union;

FOPH,

Swiss Federal Office of Public Health;

HCV,

hepatitis C virus;

HPA,

Health Protection Agency Centre for Infections in England and Wales;

HPS,

Health Protection Scotland;

I-C3,

International Conquer C Coalition;

IDU,

injection drug use;

MDA,

Magen David Adom;

MSM,

men who have sex with men;

NAT,

nucleic acid amplification technique;

PHAC,

Public Health Agency of Canada;

RKI,

Robert Koch Institute;

SCCS,

Swiss Hepatitis C Cohort Study;

SVR,

sustained viral response.

Chronic hepatitis C (CHC) is a major health burden in Europe. Recent data suggest that patients with CHC have a higher overall morbidity and mortality (1, 2). A significant portion of liver transplantation in Europe is attributable to cirrhosis and hepatocellular carcinoma because of CHC (3). The socioeconomic impact of hepatitis C virus (HCV) infection is tremendous. The incidence of complications of CHC will not decline over the next 10 years despite improved efficacy of antiviral therapy because most patients with CHC remain undiagnosed (4). Prevention of new infections, HCV screening and early treatment have the potential to reduce the overall morbidity and mortality. However, the cost-effectiveness of HCV screening may depend on the HCV prevalence (5). Decisions on public health issues such as HCV screening and prevention measures are dependent on reliable epidemiological data regarding HCV prevalence and transmission routes. The epidemiological status in Europe is continuously evolving and may vary significantly among the different regions throughout Europe (6). Thus, different countries may need different strategies to reduce the overall burden of HCV infection.

Because epidemiological data are the basis for the development of preventive measures, we aimed to systematically identify, review and characterize HCV epidemiology throughout Europe. We included Canada and Israel in our analysis because their healthcare systems and the epidemiological situation are similar to many European countries.

Methods

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

A comprehensive review of the literature was used to gather country-specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution. The countries studied were Canada, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Norway, Poland, Portugal, Romania, Russia, Spain, Sweden, Switzerland, Turkey and the UK. References were identified through two sources: indexed journals and non-indexed sources. Indexed articles were found by searching PubMed and regional databases using the following terms: ‘hepatitis C AND country name AND (incidence OR prevalence OR mortality OR viremia OR genotype OR diagnosis OR treatment OR SVR)’. Furthermore, references cited within the articles were used. Approximately 13 000 articles were reviewed and 860 were selected based on relevance. In addition, non-indexed sources were identified through searches of individual country's Ministry of Health's websites and international health agency reports. Finally, authors from each country provided government reports and proceedings of local conferences that were not published in the scientific literature. The search included publications in local languages, although reports in English accounted for over 90% of the data sources.

In every case, the prevalence values referred to the prevalence of anti-HCV antibodies, which included spontaneously cured and treated/cured individuals, whereas the HCV genotype distribution values were based on studies in the viraemic, or HCV RNA-positive population. Hepatitis C epidemiology is determined by practices, risk factors and access to care in a particular community. Community-based studies were reported, but the focus of this study was to identify/estimate prevalence in the general population. The first- and second-generation immunoassay tests provided false-positive results, which overestimated the total infected population (7, 8). Care was taken to use only studies that used the latest generation tests to estimate the country's prevalence when available or reported. In some countries, blood donor data were the main source available for prevalence. Blood donors represented a self-selected population of healthy motivated adults. The infected general population was composed of high-risk groups [e.g. injecting drug users (IDUs), dialysis patients and recipients of blood transfusions] as well as non-high-risk groups that contracted the disease through contact with infected blood (e.g. nosocomial infections, dental procedures, etc.). The donor population was a good proxy for the latter group. When multiple data sources were available, a systematic process using multi-objective decision analysis was used to rank and select the most appropriate sources (9). When insufficient data were available for prevalence, we estimated the country's prevalence using other countries in the region with a known prevalence and similar risk factors. The estimates were often for 2004 because of the lack of more recent data. When available, subtypes were assessed individually and summed to provide a value for the corresponding genotype.

Results

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

The collected data were segmented by country according to transmission risk factors, prevalence, HCV genotype distribution and diagnosed population size. The European Center for Disease Prevention and Control (ECDC) provided incidence rates for the European countries. In this publication, their estimates were used for newly diagnosed populations because most countries in the report did not distinguish between chronic and acute cases of HCV infection.

Surveillance systems also vary widely between and within countries in Europe. A publication by ECDC documented 38 different surveillance systems in 27 countries; six countries had more than one system (10). Surveillance systems vary by structure, reporting practices, data collection methods and case definitions used (11). For these reasons, caution should be exercised when comparing case reporting data across countries.

Not all countries in Europe were analysed. Those chosen were deemed representative of the region. When key data were available but a detailed analysis was not performed, the overall prevalence of anti-HCV was included in the summary map. Overall, we estimate that 11.3–14.7 million adults in Europe, including all of Russia and Turkey, are anti-HCV positive.

Canada

The Public Health Agency of Canada (PHAC) has collected data on the number of hepatitis C reported cases through its Notifiable Disease Reporting System. In addition, the Enhanced Hepatitis Strain Surveillance System (EHSSS), administered by PHAC, records risk factor information for reported cases. EHSSS covers approximately 40% of the Canadian population, with its sentinel surveillance system operating in 11 sites across Canada. The prevalence and incidence of HCV infections have been estimated through an actuarial modelling approach that included estimates of the populations at risk by place of birth and exposure category.

Risk factors

According to the PHAC, IDU was the predominant risk factor among individuals with chronic infections, accounting for 58% of cases (12). Between 2004 and 2008, IDU accounted for 63% of acute HCV infections (13). Since the introduction of blood screening for HCV in 1990, the risk of contracting HCV from blood transfusion or blood products has been virtually eliminated. However, the portion of the prevalent population with HCV acquired from blood transfusion today remains >10% (12).

Prevalence

Over the past decade, the PHAC has synthesized the most relevant data concerning the prevalence, incidence and mortality of HCV and developed models to estimate the disease burden in Canada (12, 14, 15). The PHAC estimated the populations at risk by place of birth and exposure. In addition, it modelled current and projected HCV incidence and prevalence among those born in Canada and immigrants. The model capitalized on the data available through the EHSSS. It adjusted for under-reporting and asymptomatic infection, as well as limited available epidemiological studies, specifically incident cases among IDUs.

The PHAC estimated an overall prevalence of 0.78%, or 242 500 infected individuals, in 2007. Prevalence increased with age through the fifth decade in males, and then declined, with an overall prevalence in males of 0.95%. In females, prevalence increased with age through all of adulthood, with an overall prevalence of 0.61%, resulting in a male-to-female prevalence ratio of 1.6:1. Prevalence in the adult population was 1.01% (12).

There is a paucity of prevalence studies conducted on other specific populations, such as organ tissue donors (16) and EEG clinic patients (17).

Diagnosed/incidence

Through the PHAC's Notifiable Disease Reporting System, the number of HCV cases reported annually was available from 1991 through 2008 (18). The number of reported cases increased to a peak of 19 652 in 1998 and has declined annually since (Table 1). Incidence by age and gender was estimated at 26/100 000 population (12). Incidence was higher in males (34/100 000) than that in females (18/100 000). Incidence was also the highest in 20–40 year olds, peaking in the 25–29-year age cohort, supporting IDU use as the most frequently reported risk factor. Overall, the PHAC estimated that two-thirds of the infected population was diagnosed in Canada (14).

Table 1.   Number of reported cases in Canada as reported by Public Health Agency of Canada (18)
Year1991–1999200020012002200320042005200620072008
Cases97 43917 78116 84915 96013 79513 40313 05712 12212 10512 039
Genotype

Multiple studies quantified genotype distribution in Canada (19–24). A large number of samples were collected from 138 community and academic centres throughout Canada as part of the POWeR study. The POWeR study provided expanded access to therapy among HCV-infected patients diagnosed in communities throughout Canada and referred to hepatitis C treatment clinics. This study provides the best representation of genotype distribution for the country as a whole. Genotype 1 was the most prominent genotype (60%), followed by genotype 3 (22.3%) and genotype 2 (15.4%) respectively (19). Another study reported data from the Laboratory Centre for Disease Control's Sentinel Health Unit Surveillance System representing eight health unit sites located throughout Canada. Although it sampled across the country, the study lacked representation from the larger, more metropolitan areas in Canada (21). Another study focused on patients from Saskatchewan had the same limitation (20). Conversely, other studies, whose patient samples were from Montreal, also were not the most representative of HCV genotype distribution countrywide (22, 23). However, all genotype studies show great consistency in the predominance of genotype 1 (between 60 and 67% of the study populations), with more than one study indicating genotype 1a as the dominant subtype (20, 21).

Summary

The PHAC provides country-wide estimates of incidence, prevalence and disease burden using data captured through the national surveillance system for HCV infections. Nationally collected data show that IDU is the predominant risk factor behind newly acquired cases, with younger age cohorts (20 and 30 year olds) most affected. HCV genotype 1a is the most dominant. The number of reported cases of HCV has declined in Canada since 1998. Although an estimated two-thirds of cases are diagnosed, there remains a poor awareness of risk factors in the general population (14). The PHAC recommends continued promotion of public awareness to address the HCV-positive population in Canada.

Czech Republic

There is no general screening programme in the Czech Republic. Specific subgroups are screened on a regular basis including blood donors, pregnant women, prisoners, haemodialysed patients, drug users starting weaning programmes and healthcare workers, but the data are not published regularly (25).

Risk factors

Studies on risk factors are sparse from the Czech Republic. Injection drug use has been reported as a major risk factor, increasing over the past few years, which likely accounts for a large portion of new HCV infections (26). In a 2002 study of 216 HCV-infected patients in Prague, 16% reported injection drug use. Other risk factors reported from this study include blood transfusion (15%), surgery (14%), dialysis (12%), profession-related (10%), invasive procedure (6%), sexual contact (2%) and tattooing (1%) (27). Unpublished data by authors suggested that IDU accounted for 50% of new infections in urban areas. The same studies also showed that immigration from endemic countries was contributing as a source of new infections (25).

Prevalence

Community studies have not been performed; however, it was suggested that the overall prevalence in the country was around 0.5–1% (28). When the risk factors were compared with its neighbouring countries, the prevalence of HCV infection was estimated at 1.5–2.0%, similar to Poland. Two studies reported prevalence among drug users (29, 30). One suggested that the prevalence among injection drug users was lower than that in other countries in Europe. In a study of 760 IDUs from nine regions in the country, 29.7% were found to be anti-HCV positive (30). Two blood donor studies were published and reported a prevalence between 0.2 and 0.44% (31, 32). The studies among blood donors represented healthy, adult populations that were not representative of the general population.

Genotype

The most frequent genotype in the Czech Republic was genotype 1 (26, 28, 33). HCV genotype 1b was the most frequent subtype in blood donors (33), whereas 1a was more frequent among IDUs (26). The study, most likely representative of the general population (others were limited to IDUs), reported 79.3% with genotype 1, 1% with genotype 2 and 19.7% with genotype 3 (33). In a study published in 2009 of 222 HCV-positive IDUs, 23.5% were infected with genotype 3 (26) compared with only 3% in a study of IDUs from 2001 (28). Additionally, genotype 1a was represented in only 23% of the IDU sample in 2001 (28), but 40.5% of IDUs in the 2009 study (26).

Summary

Given the lack of general population studies, Poland was used as an analogue to estimate a prevalence of 1.5–2.0%. Currently, the most common risk factor of HCV infection is IDU, especially among young people. There is no general screening programme in the Czech Republic. Specific subgroups are screened on a regular basis including blood donors, pregnant women, prisoners, haemodialysed patients, drug users starting weaning programmes and healthcare workers, but the data are not published, except for a few one-centre experiences (26, 29). HCV represents the second leading indication for liver transplantation in the Czech Republic (20–25%) after alcoholic liver disease.

France

The National Hepatitis C Prevention Program was implemented in France in 1999 and renewed in 2002 to reduce HCV transmission, increase screening and improve access to treatment (34, 35). The National Institute for Surveillance set up a national surveillance network, and two national population-based prevalence surveys were conducted in 1994 (36) and 2004 (34, 37, 38) among metropolitan residents. The 2004 study surveyed 14 416 residents aged 18–80 years. The metropolitan residents accounted for approximately 70% of the 2004 total population. The survey excluded active drug users and samples from rural residences, and it likely over-represented the immigrant population, but it was one of the most robust studies in the region and represented the best dataset available for risk factors, prevalence and percent diagnosed.

Risk factors

There are numerous studies on the HCV risk factors for existing and new infections (36–53). The most recent and robust study in the prevalent population reported the analysis of the 2004 national survey (37). A multivariable regression was used to identify the key risk factors. The most commonly identified risk factors included a history of surgery (88%), piercing (51%), history of endoscopy (43%), blood transfusion before 1992 (35%), over 10 sexual partners (29%), lifetime nasal drug use (28%) and lifetime IV drug use (26%). Although only 26% of the prevalent population reported lifetime IV drug use, it was the largest factor in predicting a positive HCV infection. Through regression analysis, other important factors identified were lifetime nasal drug use, born in a high-endemic country, blood transfusion before 1992, tattoo and beneficiary of medical welfare. Analysis of newly diagnosed individuals (2001–2007) by the French Institute for Public Health Surveillance revealed gender differences between male and female risk factors. Males showed high rates of IDU (40–47%) as a key risk factor, while females showed a lower range (17–21%). Females, on the other hand, showed transfusions as the major risk factor (33–39%). Overall, IDU was the largest risk factor by percentage (32%), although only slightly over transfusions (26.5%) (54). Because active drug users were not part of the cohorts analysed, IDU could account for a larger portion of the infected population.

Sixty-four positive and 227 control cases were studied to capture risk factors in the incident population (40). The most commonly identified risk factors included anaesthesia (33%), general anaesthesia (22%), invasive diagnostic procedure (23%), drug use (17%) and IDU (16%). Similar to the national survey, the authors took care to compare data of the infected population with a control group and use regression analysis to identify the key risk factors. Even though one-third of the incident population had anaesthesia at some point in time, it had a lower matched odds ratio than some of the other factors because of the presence of the same risk factor in comparison with the control group.

Earlier studies supported the above conclusions. A 2006 study reported the importance of nosocomial transmission (41). All anti-HCV-positive individuals resulting from a population-based prevalence survey confirmed that IDU (odds ratio=29.2), history of transfusion (odds ratio=7.0) and absence of paid employment (odds ratio=3.1) remained statistically significant after an exploration of many risk factors in the study (36). In a study of newly diagnosed patients, drug use was reported as the main risk factor for HCV infection (51, 33 and 31% in 1997, 2000 and 2003 respectively) (55). In studies tasked to correlate genotype with risk factors among chronic HCV patients, recent drug use was found to be significantly linked to increases in genotypes 1a and 3a, lending further credence to the large and recent role for IDU transmission (56, 57).

Prevalence

There were a number of studies estimating prevalence in the general population (34–38, 58–60). The most definitive results are provided by the 2004 prevalence survey analysis and showed a rate of 0.84% for 18–80 year olds (0.71% for 20–59 year olds) (34, 37, 38). The prevalence was distributed bimodally (ages 40–49 and 60–69), with the lowest prevalence among 18–29 year olds (37). The results of the 1994 study showed a prevalence of 1.05% using a similar methodology with a smaller sample size (n=6283) and a more limited age range (20–59 years) (36). Comparison of the two studies showed that HCV prevalence declined from 1.05 to 0.71% in individuals 20–59 years of age between 1994 and 2004. The decrease was attributed to a decrease in incidence over time because of the positive impacts of a syringe programme and the application of standard precautions in healthcare settings (34, 35). Similar results were obtained by other investigators. A prevalence of 1.3% was reported in a study based in Lyon with a large sample size (58). Other studies reported a 1999 prevalence of 1.1% for the entire country (59) and a 1996 prevalence of 1% (60). While population-based studies are essential for determining the overall prevalence in the country, it is important to note that active drug users are less likely to participate in health surveys, which may result in rates that are lower than the actual national average.

There were a number of studies in subpopulations as well. A 2004–2005 national survey found prevalence among IDUs to be nearly 60% (61), consistent with the 2004 national survey results of 56% (37), while a prevalence of 73% was reported among a smaller sample of IDUs in 2002 (62), potentially indicating a decline in prevalence among IDUs in France. A number of separate studies reviewed the prevalence of HCV among blood donors (63–68). This subpopulation represents healthy adults without previous infections. Between 1993 and 2000, the prevalence declined from 1.23 to 0.23% among blood donors, similar to the observed decline in the general population (63). Other subpopulations studied include HIV-positive patients, pregnant women and various high-risk groups (43, 45, 68–74).

Diagnosed/incidence

True incidence data in the general population were not available. An incidence of 9/100 person-years among IDUs and an annual incidence from 0 to 17.5% among haemodialysis patients from 1981 to 1991 have been observed (58, 75–77). Other studies that reported incidence were actually studying the newly diagnosed rate. For example, an assessment of the southwest France's campaigns to evaluate the implementation of HCV guidelines estimated a newly diagnosed rate of 43/100 000 persons in 1997, declining to 26/100 000 by 2003 (55).

The 2004 national prevalence study showed that 57.3% of anti-HCV-positive persons were already aware of their seropositivity or were previously diagnosed. Among the anti-HCV-positive study population, 93.2% of past or current IDUs, 66.5% of individuals who had transfusions before 1992 and 25.6% of the other population were previously diagnosed (37).

Genotype distribution

Numerous genotype distribution studies dating back to 1995 showed genotype 1 to be the most predominant (41, 56, 57, 78–85). In the largest and best sample of HCV genotypes, 1769 samples were collected from 26 referral centres; 57% of the sample was genotype 1, 9.3% genotype 2, 20.8% genotype 3, 8.9% genotype 4, 2.7% genotype 5, 0.2% genotype 6 and 0.9% mixed genotypes (57). Similarly, a 1999 study showed genotypes 1 and 3 as the most common genotypes (57 and 22% respectively) (56).

Summary

France has the most active programmes to manage HCV infection through screening, improving access to treatment and reducing transmission. The National Institute for Surveillance runs national surveys to determine the prevalence, risk factors and profile of the infected population. Investigators have used regression to determine the risk factors that contribute to new infections and have shown IDU to be a key risk factor with most new infections in younger populations. The epidemiology of HCV in France is marked by a relatively low prevalence (0.84% in 2004), which has declined from 1.05% in 1994. The most common genotype is 1, with 1b dominating; the second most common genotype is 3.

Germany

In Germany, there is no general anti-HCV screening programme. Newly diagnosed cases of HCV infection have to be reported to the Robert Koch Institute (RKI), but there is no discrimination between newly diagnosed chronic or acute HCV infections. There are national guidelines in place that recommend anti-HCV testing in all patients with elevated ALT and in risk groups (86).

Risk factors

Risk factor data are collected as part of the national surveillance of HCV in Germany. For HCV cases reported in 2009, 34% indicated IDU (87). In confirmation of IDU as the primary risk factor for HCV infection in Germany today, one study recorded risk factors for over 10 000 patients from 352 centres throughout Germany. Similar to national surveillance data, this study found that the vast majority of patients (45.5%) reported IDU as the primary transmission factor for HCV (88). Other significant risk factors reported by Huppe and colleagues and RKI were transmission through blood products (17.4%) and medical procedures (9.0%). As blood products have been screened for HCV in Germany since 1991, and no HCV transmissions have been reported because nucleic acid amplification technique testing became mandatory in 1999, the risk factors reported above represent the distribution in the prevalent population (89). In a cohort of acute HCV patients admitted for antiviral therapy, IDUs were significantly younger than non-IDUs, while the proportion of patients who acquired HCV by medical procedures increased with age (90). Clearly, IDU is driving newly acquired cases for the past decade or more. Another recently identified potential risk factor is men who have sex with men (MSM), particularly HIV-positive MSM, and is the subject of ongoing scientific studies (87).

Prevalence

A few German studies address prevalence in specific subgroups, such as children or surgical patients (91–95). For example, one study reported a prevalence rate of 2.4% among a large cohort of 13 823 screened emergency room patients in 2008 and 2009 (95). Others limit the study population to IDUs, with prevalence findings in excess of 60 to over 80% (94, 96–99). There is also limited prevalence research involving blood donors, most demonstrating a prevalence of <0.5% in this subpopulation (100–103). However, none of these studies lend themselves to extrapolation to the general population in Germany.

There have been two community-based prevalence studies in Germany. From 1993 to 1996, 5312 randomly selected individuals, ages 18–70, were tested. Individuals were selected from small, medium-sized and large cities in five different German states, providing a good representation of the German adult population. An overall prevalence of 0.63% was recorded, 0.90% in females and 0.41% in males. In both males and females, prevalence increased with age, with the exception of the 31–40-year age cohort in females (104). The findings from the 1998 German National Health and Examination Survey, with samples obtained from 6748 adults throughout Germany (ages 18–79), showed an overall prevalence of 0.4%, 0.3% in males and 0.4% in females (105). Both studies found elevated prevalence in females, although the variance between genders was not statistically significant. A study of 1064 orthopaedic surgery patients in east Germany identified no cases of HCV, indicating the potential of different prevalence rates in West Germany and East Germany (106).

Diagnosed/incidence

Newly diagnosed incidence is reported annually by the RKI. The latest data from 2009 indicate an incidence rate of 6.6/100 000 inhabitants in Germany (87). Age and gender distribution show peak incidence in both males and females in the 25–29 age cohort, with male incidence in excess of female incidence at a ratio greater than 2:1 in this same age cohort. Newly diagnosed cases have declined from 2004 to 2009, with an annual rate of decline between 8 and 13% (Table 2) (87). It was estimated that 100 000 individuals, or 38% of the prevalent population, had been diagnosed as of 2004 (107).

Table 2.   Diagnosed cases reported by Robert Koch Institute (87)
Year200420052006200720082009
Number of cases903682747449686762235412
Genotype

There are several studies reporting genotype distribution (108–112); all provide a local or a regional analysis on small subsets of patients. The most representative study reported genotype distribution for a large cohort of patients (9455) located throughout Germany (88). Genotype 1 represented 61.7% of patients, genotype 2 in 6.9%, genotype 3 in 28%, genotype 4 in 3.2% and other genotypes in 0.2% of patients. Over the study period, from 2003 to 2005, there was a decline in the percentage of patients with genotype 1 and an increase in the percentage of patients with genotypes 2 and 3. Additionally, the mean patient age was higher for genotype 1 and lower for genotype 3.

Summary

National surveillance for HCV infection occurs in Germany, and provides information on the epidemiological trends of HCV. The RKI as well as other researchers identified the majority of newly diagnosed cases in younger age cohorts that are also attributable to IDU. An increase in genotype 3, with a decline in the percentage of patients infected with genotype 1, also indicate a trend towards the increased significance of IDU in perpetuating the disease in Germany (genotype 1 predominates in patients with post-transfusion hepatitis, while genotype 3 is seen more commonly in patients acquiring HCV through IDU) (88,110). The RKI has called for increased surveillance, supplemental epidemiological studies and targeted prevention measures in the at-risk population of IDUs in Germany.

Greece

In Greece, there are no national screening efforts. HEPNET-GREECE (Hepatitis Network–Greece) for hepatitis C is a national retrospective–prospective study initiated in 2003 that is sponsored by the Government and provides useful information regarding the epidemiology and course of chronic hepatitis. In addition, there are available data on prevalence, risk factors, diagnosed cases and genotype distribution from several studies in blood donors or patient samples.

Risk factors

A relatively small number of studies identified the risk factors associated with HCV transmission in Greece. One study of 434 unselected patients with chronic HCV established the same two risk factors in the study population as are located throughout Europe: transfusion (39%) and IDU (18%). Blood screening for HCV was initiated in the early 1990s. As expected, Savvas et al. (113) found that infection acquired before 1981 was more commonly related to transfusion, while infections after 1981 were associated with IDU. With a somewhat larger study population of 1229 CHC patients, blood transfusion was identified as the source of transmission in 25% of enrolled patients, and 30% of enrolled patients had a history of IDU, demonstrating again the two primary causal routes in the prevalent population (114). Another study included 309 HCV patients with origin and/or residence in Thessaly, Greece. After identifying three municipalities with a higher frequency of anti-HCV positivity than others, they investigated the potential risk factors for the variance. The sole risk factor more frequently identified in these municipalities was a history of the use of non-disposable, multiple-use glass syringes for medical purposes. Therefore, iatrogenic transmission may be responsible for pockets of high prevalence of HCV throughout Greece, particularly in the older population (115). In the first community-based study in the general population, similar risk factors were reported in the southwestern part of the country: blood transfusion, IV drug abuse and history of operation. In this region, non-disposable syringes were used extensively for parenteral anti-microbial treatment in the past, allowing one to conclude a potential association with anti-HCV positivity and past iatrogenic transmission (116). Recently, Raptopoulou and colleagues reported epidemiological data from 2817 patients followed at 20 hepatology centres throughout Greece between the years 1997 and 2006. The study showed that 90% of HCV infections acquired after 1992 belong to the IDU group, and therefore, in the near future, Greek hepatologists will be facing a significant number of young patients with cirrhosis or hepatocellular carcinoma (117).

Prevalence

The estimated prevalence was 1–1.9%. There were a number of prevalent studies published but nearly all were in subgroups (pregnant women, military personnel, company employees and volunteer blood donors) and reported a range of 0.37–1.5% (116, 118–124). Researchers identified communities with prevalence well in excess of 1% because of a history of improper sterilization techniques. One rural community on the island of Zakinthos had an anti-HCV positive rate of 6.8% (118), while a 10.9% prevalence was recorded for individuals attending primary care services on the island of Crete (125). Other studies also demonstrated an elevated prevalence of HCV in high-risk populations (126–128). No cases were identified in two separate studies that included only children (129, 130).

Diagnosed/incidence

Incidence was estimated at 5.0/10 000 in Greece in 1990 (114). A doubling in the incidence rate occurred from 1970 to 1990, propelled by genotype 3, and to a lesser extent, genotype 1b. Modelling annual incidence rates from prevalence and the natural history of HCV in a cohort of CHC patients, researchers arrived at a similar finding of 5.0/10 000 person-years in the late 1980s (131). The incidence of reported HCV cases in Greece has declined since 1999; the Hellenic Centre for Infectious Diseases Control estimates a 50% decline in HCV incidence since 1990 (132).

Although reported HCV cases do not represent the entire incident population because of under-reporting and the asymptomatic nature of the disease, it is likely that a downward trend is apparent. Still, the number of cirrhotic and HCC cases as well as HCV-related mortality will only decline in the next 30 years if complete elimination of new HCV infections is achieved from 1990 onwards (131). Therefore, while the pool of individuals newly acquiring HCV may be declining, the disease burden will remain in the immediate future.

Genotype

Recently, the results were reported from the large HEPNET-GREECE cohort study, with 2817 patients included in the analysis (117). One study relied on patients in Athens (113); another had the added benefit of recruiting CHC participants from multiple clinical sites throughout Greece (114). All studies reported similar changes in HCV genotypes during the last two decades. The studies reveal a remarkable similarity of estimates: genotype 1 is reported as the most prevalent (47, 46.9 and 45.1%), with genotype 3 as the next most prevalent (27, 28.1 and 34%). Genotype 4 was found in 15.2, 13.2 and 13.9% of patients, and genotype 2 in 8.3, 6.9 and 7% of patients (113, 114, 117).

All studies report an association between genotype 1 and blood transfusion while genotype 3 was associated with IDU. In addition, genotype 1 was associated with advanced age vs. genotype 3 and younger age cohorts. Genotype 4 was present more frequently relative to other European countries. It was detected in approximately 15% of the population and was equally distributed among patients with different modes of transmission (113, 114, 117). Genotype 4 seems to be imported to Greece both from immigrants and returning expatriate communities who lived in Africa. Data tracking the temporal pattern of incidence specific to genotype revealed a moderate increase in incidence associated with genotypes 1 and 4 (1.3–1.6 times), with a significant increase in genotype 3-specific incidence (13 times) from 1970 to 1990. These data indicate that IDU was the precipitating factor in recent decades in Greece.

Summary

Epidemiological data of HCV infection in Greece are limited. Studies of blood donors and reports from Liver Units are the main sources of data. The HEPNET-GREECE cohort nationwide study is the most definite source for epidemiological data in Greece. The epidemiological characteristics of HCV infection can be summarized as follows: (i) there are some isolated areas in Greece where the prevalence of the disease is high (6–10%) because of unsafe parenteral injections or invasive medical procedures, (ii) there is a significant change in genotype distribution because of an increase of illegal drug use, (iii) genotype 1 is predominant among chronically infected patients, while genotype 3 incidence has been growing rapidly (increased 13-fold) and (iv) 15% of infections are genotype 4.

Hungary

Limited national data are available from the National Centre for Epidemiology in Hungary, mainly results of a national seroepidemiological study performed in 2000 that estimated the overall number of anti-HCV-positive individuals. The National Communicable Disease Reporting System captures only acute cases detected annually, and reporting is not mandatory. No national screening programme is in place.

Risk factors

Only two studies examined possible risk factors. Previous surgery, having more than three pregnancies, blood transfusion and tattooing were associated with HCV infection (133, 134). High rates of HCV infection in the IDU population also indicate IDU as a risk factor (135), although the rates of IDU in Hungary are reportedly lower than that in other European countries (136).

Prevalence

Based on a national seroepidemiological study in 2000 by the National Centre for Epidemiology in Hungary, there were an estimated 60 600 HCV cases in Hungary, which represented 0.6% of the population (135). In 2001, a study of 477 hospital workers found a prevalence of 2.7%, indicating that occupation could be a potential risk for infection (137). A large blood donor study in south Hungary in 2001 indicated that the prevalence of HCV in 45 719 blood donors was 0.4% (133). Earlier blood donor studies reported slightly higher prevalence rates. One reported a prevalence of 0.73% in 15 864 blood donors (134); another screened 9707 blood donors and found a prevalence of 0.53% (138). Studying 120 children who received one or more blood transfusions before implementation of anti-HCV screening, a rate of 1.7% was observed (133).

Barna et al. (134) found that prevalence increased with age. Mihaly et al. (137) also reported an increased prevalence with age, from 0% in those <21 to 9.5% in those older than 50 years.

Diagnosed/incidence

The number of cases per 100 000 inhabitants decreased slightly from 0.4 in 2001 to 0.2 in 2005 (10, 135). Only acute HCV cases are reported annually via the national communicable disease reporting system (135), and thus represent an underestimate of the total incidence measure for Hungary.

Genotype

The most common genotype in Hungary is genotype 1b, with estimates ranging from 54.5 to 85.5% (137, 139). A study including a small number of workers from a hospital treating patients with tropical and infectious disease most likely does not accurately depict the genotype distribution for the rest of Hungary (137). Reporting in 211 patients with CHC, genotype 1b (85.5%), 1a (6.0%), mixed (5.0%), 1a+1b (3.0%) and 3 (0.5%) were observed (139). In a more recent study including 118 patient samples, the overwhelming majority of patients were genotype 1 (94.1%). Genotype 2 was identified in 0.8% of patients, genotype 3 in 3.4% of patients and genotype 4 in 1.7% of patients (140). In a small study of patients with CHC, all were genotype 1 (141), while 98% of the 47 blood donors examined were genotype 1 (138).

Summary

The overall estimated prevalence of HCV infection is low (0.6%) in Hungary; the relatively low rate of IDU may contribute. Most chronic HCV cases diagnosed today were acquired before 1992 via transfusions and other blood products. Over 90% of chronic infections are genotype 1.

Israel

Healthcare is universal and participation in a medical insurance plan is compulsory. Health insurance is covered by four HMOs with Clalit Health Services (CHS), the largest medical provider, managing close to 60% of the population. There is no HCV patient registry in the country, but data are collected and maintained by different health services. Given the large immigrant population, substantial data exist on seroprevalence and genotype by country of origin. Some of the data reported here are based on previously unpublished data reported by the author using a database of 3 926 182 individuals insured by CHS between 2001 and 2010, of which 789 689 were tested for HCV (20% of all ages and 29% of age >20 years) (142).

Risk factors

Multiple researchers identified immigration from the former USSR as one of the key sources of HCV infections in the country. The authors suggested that mass vaccination using non-disposable needles in the former Soviet Union and the spread of infection within families could be the cause of a higher prevalence among immigrants (143, 144). The risk factors among immigrants and native Israelis were assessed in a case–control study of 434 blood donors (143). IDU was associated with HCV infection in both groups, accounting for 14% of cases in native Israelis and 10.2% of cases in immigrants. Another risk factor was blood transfusion, which, before 1990, accounted for 42% of native Israeli cases and 11.7% of immigrant cases. Other strong risk factors among native Israelis included close contact with infected individuals and surgery. The risk factors identified in the former Soviet Union immigrants included gum surgery, hospitalization without surgery and receiving injection therapies (143). IDU was found to be a significant risk factor among 29 acute hepatitis C patients, accounting for 20.6% of infections, but a higher percentage of patients (65.5%) could have been exposed through medical procedures (145).

Prevalence

Most of the studies looked at specific subgroups in the population, with many focusing on immigrants. While immigrants made up 40% of the tested population, they accounted for over 70% of HCV infections (142). Studies involving only immigrants indicated a wide range of prevalence rates from 1.3 to 26.5% (144, 146, 147).

Community studies assessing HCV prevalence were not published, and only a few blood donor studies were performed (148–150). The best estimate of prevalence came from unpublished data from CHS. Among 789 689 individuals tested, 1.96% were HCV antibody positive in 2001–2010. The infection rate reached more than 4% among immigrants from the former USSR (142). The Magen David Adom National Blood Services reported an overall prevalence of 0.1% among all blood donors, with a higher prevalence among immigrants (0.8%) as compared with natives (0.04%) (151). The prevalence among IDUs was 75%, consistent with that of other countries (152–154).

Genotype distribution

The CHS data showed a genotype distribution of 1 (70%), 2 (8%), 3 (20%) and 4 (3%) among natives (142). Only one published study reported the genotype among infected individuals, but the sample size was small (n=29) (155). Both studies showed that the predominant genotype was 1.

Diagnosed/incidence

Analysis of CHS data showed that newly diagnosed cases declined from a peak of 2500 in 2001 to <1000 per year in 2010 for a total of 16 183 cases in 2001–2010. As CHS covered approximately 60% of the population, it was estimated that approximately 27 000, or 33%, of the infected individuals were already diagnosed. The Ministry of Health reported that the number of acute HCV patients was 0.351 per 100 000 in 2005–2009, a decline from 0.811 per 100 000 from 2000 to 2004 (156). However, this represented only reported cases and there were no estimates for under-reported or unreported cases.

Summary

While there were a few recent studies describing the epidemiology of HCV, data from CHS provided the best estimates for the country. The prevalence was estimated at 1.96%, with a higher rate among immigrants. Genotype 1 was predominant, with subtype 1b being more common. Risk factors included IDU, blood transfusion before 1990 and other forms of iatrogenic transmission.

Italy

Hepatitis C virus screening and surveillance is minimal at a national level in Italy. There is an active surveillance programme only for newly detected symptomatic acute cases. Instead, the majority of our knowledge comes from regional or local studies, which are difficult to extrapolate to the general population.

Risk factors

Risk factors for HCV infection have traditionally been related to nosocomial and healthcare-related transmission, or from IDU. The high prevalence of HCV in the elderly, particularly in the central and southern regions, can be explained by the extensive use in the 1960s to 1970s of some popular therapies (vitamins, nutrients, etc.) given by parenteral injections with multi-use syringes.

Recent risk factor analyses confirm nosocomial and healthcare-associated transmission as the major routes of transmission in Italy. Researchers studied a southern Italian municipality, Apulia, to estimate prevalence and risk factors. They reported blood transfusions (26%), glass multi-use syringes (88%), surgical interventions, household contacts and IDU as the major risk factors (157). Others used a sample based in Naples, an area with a known elevated incidence of liver cancer. This study estimated HCV and HBV prevalence and performed an extensive risk factor analysis. The risk factors included household contacts (10.7%), sexual intercourse with HCV-positive partners (29.6%), IDU (27.8%), history of blood transfusions received before 1993 (27.6%) and those with prolonged dental therapies (8.9%) (158). A study conducted on the Camporeale, Sicily, population provided further evidence for hospital-based transmission. A population-based, random sample of nearly 800 individuals indicated that the use of glass multi-use syringes, hospitalizations, surgical interventions and blood transfusions, as well as age older than 45 years were independently associated with HCV infection. An initial association with glass multi-use syringes was also suggested, but may have been a surrogate measure for hospital admission generally (159). Based on the sample size and its comparability with other recent studies, the best risk factor estimates for blood transfusions (27.6%) and injection drug users (27.8%) are the estimates generated by Fusco et al. (158).

Prevalence

A large number of recent prevalence estimates exist (157–200). These, however, vary substantially by study location and sample type and represent considerable heterogeneity of estimate. This heterogeneity is likely marked by two distinct waves of disease. There is a marked age-specific prevalence distribution and evidence that nearly 60% of HCV-positive subjects are currently older than 65 years (201); these mark the first wave. The second, smaller wave is apparent in urban areas of northern Italy and may be marked by more serious infection, potentially because of the comorbidities of HIV and alcohol abuse. Certainly, there is also a significant North–South increasing gradient in the prevalence of chronic HCV infection, but pockets of high prevalence in close rural communities have been described in different regions of the country (165).

In a southern Italian town, an estimated overall age-adjusted prevalence of 2.6% was reported. The study reported male prevalence rates (3.1%) slightly higher than females (2.4%) (157). A study carried out in Naples reported a much higher prevalence in 2008 of 7.5% (158). Another study in a northern Italian population estimated a prevalence of 2.6% (161). The best estimate of prevalence likely arises from Ansaldi et al. (165), in 2005, whereby an age-adjusted estimate of 4.4% (2.7% overall observed rate) was derived from a number of samples submitted to a diagnostic laboratory for alternate purposes throughout Italy. A clear north–south gradient was demonstrated, with a reported age-adjusted prevalence of 1.6% in the north, 6.1% in central Italy and 7.3% in the south. Because of an increase in prevalence with age, the prevalence in the adult population was 5.2%. Pockets of comparatively high prevalence have been reported in central and southern Italy (11.1, 16.3 and 22.4%), but appear to outlay the reasonable range for a population-based estimate (163, 169, 176).

Diagnosed/incidence

Estimating incidence has been historically difficult, as the recent studies vary substantially. In Italy, there is an active surveillance programme for the incidence of symptomatic acute hepatitis cases reporting a rate of 0.2/100 000 in 2009 for HCV, but this is certainly a significant underestimation, as HCV infection is rarely symptomatic during the acute phase. The most recent incidence reports from 2008 suggest a decline in overall incidence from 1997 to 2005 (range 2.6/100 000–0.7/100 000 person-years) (10). One study estimated a rate of 4.13/100 000 persons from a blood donor population from 1996 to 2000 (160). Another study reported a rate of 50.3/100 000 from a northern Italian population in a study ranging from 1986 to 1996 (172). Yet another reported a rate of 1.4/10 000 person-years (or 14/100 000) around Rome over a 7-year time period ending in 2002 (174). In blood donors from 1994 to 1999, a rate of 2.41/100 000 person-years was recorded (202). The historical data decline in incidence rate is likely due to improvements in historical risk factors like blood transfusions and other parenteral sources because of improved testing for HCV. The best estimate for incidence may be from Rome; however, it is based on a subsample and should be considered with caution at 1.4/10 000 person-years for 2002 (174). It was estimated that 300 000 individuals, or 12% of the prevalent population, had been diagnosed as of 2004 (107).

Genotype

A number of studies have estimated the genotype distribution of HCV subtypes in Italy (157, 159, 165, 203–208). The largest study comes from southern Italy (208). These data appear to match well with other researchers' work (165, 207). Comparing all studies, genotype 1b appears to be the most frequent type of infection (30.7–60%), with genotype 2 following (21.3–34.8%). The best estimate is likely from Matera et al. (208), in which genotype 1 was estimated at 62%, genotype 2 at 27%, genotype 3 at 7% and genotype 4 at 5%.

Summary

The epidemiology of HCV in Italy has some unique features: a stark difference in age distribution, a clear north–south prevalence gradient and evidence of very high endemic areas of HCV infection that often occur in rural areas of the country. The high prevalence of HCV in the elderly particularly in the central and southern regions can be explained by the extensive use of historically important and popular therapies given with multi-use syringes. The risk factors for HCV infection in Italy have been traditionally related to nosocomial and healthcare-related sources. Recently, IDU has been implicated, but the country's low incidence numbers suggest this as less of a problem than selected northern European countries. Genotype 1 is most predominant; however, genotype 2 is more highly represented than in other countries in Europe. Despite the large numbers of studies reviewed, no truly representative estimate exists; future projections may be significantly improved with general population studies.

Norway

The Oslo Health Study, a large population-based study conducted in 2000–2001 and commissioned in part by the Norwegian Institute of Public Health, is the most definitive source of population-level HCV estimates for Norway. National screening guidelines do not exist.

Risk factors

The results from the Oslo Health Study provided the best estimates with respect to risk factors. Among 72 infected individuals identified in a community sample, the most common risk factor reported was injection drug use at 67%. Blood transfusion was also identified as a possible mode of transmission (6%); however, 24% of the infected individuals did not have a known risk factor (209). In another study, IDU was also reported as the main risk factor (28%) among a group of 51 HCV patients referred for possible liver transplantation (210).

Prevalence

The few studies in Norway reported a prevalence of <1% (209, 211–214). The most representative study was the Oslo Health Study, reporting a prevalence of 0.70%, with the highest prevalence seen in ages 40–45. This study included 11 456 individuals ages 30 and older from a random sample of community members in Oslo during 2000–2001. This study did not include active drug users, who have an exceptionally higher prevalence rate (an 81% prevalence rate in the IDU population was observed in 2009) (209, 215). While population-based studies are essential for determining the overall prevalence in the country, it is important to note that active drug users are less likely to participate in health surveys, which may result in rates that are lower than the actual national average. In Norway, the prevalence of IDU is near the median for countries reporting to the European Monitoring Centre for Drugs and Drug Addiction (136).

Specific groups such as IDUs have been studied by researchers and report values that are substantially higher than the general population, ranging from 56 to 93% depending on the year (216, 217). Other groups such as pregnant women have been studied and prevalence rates similar to that of the general population Oslo Health Study have been reported (213). One blood donor study has been reported that yielded a rate much lower than that of the general population (0.11% compared with 0.70%) (214).

Diagnosed/incidence

Incidence rates as reported to the ECDC are similar to the low prevalence rates reported previously. These have ranged from 0.4 to 0.8 cases per 100 000 people from 1996 to 2005 (10). However, it is believed that the reported rates are underestimating the actual incidence rate. Given that the size of the HCV prevalent population is approximately 30 000 individuals and the viral epidemic reached Norway 40 years ago, there are approximately 10–20 cases per 100 000 persons per year (218).

Genotype

The most representative study for genotype distribution comes from the Oslo Health Study. In this study, the most common genotype identified from a community sample was genotype 1 (61.5%); both subtypes 1a and 1b were represented equally (28%). Genotype 3a was also a commonly identified genotype, in 28% of patients, and genotype 2b in 10.5% of patients (209). Another researcher found genotype 3 to be the most common (50%). However, this study consisted mainly of IDUs, which may explain the difference in the genotype distribution between the two studies (219).

Summary

Hepatitis C virus prevalence is relatively low in Norway, estimated to be <1% in the general population. The rate of new infections has also remained low, with a reported incidence of 0.4–0.8/100 000 from 1996 to 2005. However, few recent population-based studies have been performed, indicating the need for further research to fully understand the current trends of infection in this country. A significant portion of new cases are likely arising from IDU among the younger generations.

Poland

Hepatitis C has been a notifiable disease in Poland since 1997. The surveillance system in Poland covers both acute and newly detected chronic HCV. Outside of these newly diagnosed data reported annually, no national-based statistics are available for HCV. Poland does not have a national screening programme in place.

Risk factors

In an early study from 1991 to 1995, in 107 patients with acute and chronic HCV infection, surgery (28%) and hospitalization in a non-operative ward (17%) were common risk factors (220). More recent studies have identified additional risk factors. From a group of 250 HCV-infected individuals, blood transfusion before 1993 was the most frequently reported risk factor, accounting for 26.8% of infections. This was followed by healthcare-related occupational exposure (13.6%) and IDU (8.8%). Drug use was significantly higher in younger males; 82% of infected drug users in this study were men under the age of 45. In females under the age of 45, the majority of infections (60%) were accounted for by blood transfusion before HCV screening. This high percentage was likely because of the use of transfusion to increase haemoglobin levels during postpartum iron deficiency (221). In another report, the risk associated with medical procedures was assessed. In 194 non-IDU patients, transfusions, healthcare occupation, minor surgery and dental care were found to be significant sources of infections (222). Similarly, in a study of voluntary blood donors and hepatitis C patients, the main infection routes identified were associated with diagnostic and therapeutic procedures performed in medical service units (223). A large study including 17 930 persons identified the following significant independent risk factors for anti-HCV positivity: more than three hospitalizations in a lifetime [odds ratio (OR): 1.8], blood transfusion before 1992 (OR: 2.9) and IDU (OR: 6.2) (224).

These reports highlighted the importance of healthcare in the transmission of HCV, both through procedures and employment in the field. The risk of infection from IDU was suggested to be lower in Poland than that in other countries (221), but this could be because of the fact that studies to date were performed in healthcare settings that under-represent the IDU population.

Prevalence

The Institute of Infectious and Parasitic Diseases at Warsaw Medical University reported that 750 000 individuals were infected with HCV in 2006 corresponding to a prevalence of 1.9% (135). In a fairly large study of 2561 non-randomized volunteers, a prevalence rate of 1.9% was found (225). Another study included 143 non-randomized volunteers with risk factors for chronic HCV, but who had not been diagnosed, and found a prevalence of 2.09% (226). One of the best estimates for the prevalence in Poland comes from a study of 1069 students, where the prevalence varied between 1.4% in medical students and 1.9% in students in non-medical majors (227). A recent study including 9029 healthcare workers and 8901 consecutive patients of large multispecialty hospitals and outpatients not involved in the management of liver diseases reported a prevalence rate of 1.42% among healthcare workers and 1.92% among patients (224). Another study included 278 infants aged 3–12 months and found no cases of HCV, even in children who had been hospitalized at least one time, indicating that infection is rare in the first year of life (228).

In a large blood donor study of 4 233 119 donors between 1994 and 2003, a prevalence of 0.46% was reported, with a decreasing trend in prevalence across time (229). In a smaller study of 44 298 blood donors between 1998 and 2000, a prevalence of 0.5% was recorded, with no differences among gender and age (230). Bielawski et al. (225) also found no differences by age.

While no studies reported a difference by age, there may be a difference in rates by gender. According to three studies, males had a higher prevalence than females. One study found that prevalence was significantly higher in men (2.3%) compared with women (1.7%) (225). While only 31.5% of another study population was male, all three cases were found in males (226). Flisiak et al. (224) reported male sex as a significant independent risk factor for anti-HCV presence (OR: 1.7).

Diagnosed/incidence

Hepatitis C has been a notifiable disease in Poland since 1997. All symptomatic cases, both acute and chronic, are reported to the National Institute of Public Health. Based on reported cases, the number of cases per 100 000 inhabitants has ranged from 5.05 to 7.9 between 2000 and 2008, with the most recent number diagnosed of 6.17/100 000 in 2008 (231–239). The variation in the number of cases is likely because of a surveillance artefact associated with a new case definition (231, 232, 239).

Consistently across the years, there have been a larger number of cases in men than that in women (7.1/100 000 vs. 5.3/100 000 in 2008), and urban areas have shown case rates twice that of rural areas (7.7/100 000 vs. 3.8/100 000 in 2008). Peak incidence was observed in the 50–65-year age cohort in both males and females in 2008 (231). The Institute of Infectious and Parasitic Diseases at Warsaw Medical University estimated that 20 000 cases out of 750 000 infections have been diagnosed corresponding to a diagnosis rate of 2.7% (135).

Genotype

The most common genotype in Poland is genotype 1. In 179 patients with chronic liver disease, 57.5% were genotype 1, 31.3% genotype 3 and 4.8% genotype 4, with a significant increase in genotype 3 in those infected after 2000 compared with those infected before 2000, from 19.1 to 38.9%. Genotype 1 was found mainly in those whose HCV was thought to be acquired through blood transfusion (68.8%), with 34.8% of those acquired thorough injection drug use. Genotype 3 was most prevalent in IDUs (240). Another study examined three different groups, and while genotype 1b was the most prevalent, the distribution of the genotype varied by group, which may indicate which genotypes lead to more serious disease. In 50 blood donors who were anti-HCV negative but HCV RNA positive (indicating recent infection), 36% were genotype 1b, 2% genotype 1a, 40% genotype 3a, 14% genotype 4 and 8% mixed. Among 70 anti-HCV-positive blood donors, 75.7% were genotype 1b, 4.3% genotype 1a, 14.3% genotype 3a, 4.3% genotype 4 and 1.4% genotype 6. Among 170 hepatitis patients, 85.3% were genotype 1b, 0.6% genotype 1a, 10.6% genotype 3a, 1.2% genotype 4 and 2.4% mixed (241).

Summary

The best estimate for the prevalence of HCV infection in Poland is approximately 1.9%. The reported number of cases of HCV infection has increased from 5.4/100 000 inhabitants in 2000 to 7.7/100 000 inhabitants in 2006. Whether this is a true increase in the number of cases or a surveillance artefact associated with a new case definition is undetermined. There are a larger number of newly diagnosed cases in men than women, and men are generally diagnosed at a younger age, indicating different modes of infection between the genders. The majority of chronic infections in Poland are genotype 1.

Portugal

There is minimal epidemiological research for HCV in Portugal, with only one published national estimate. National screening guidelines are not in place.

Risk factors

Only one study provides risk factor analysis; it identifies IDU (58.7%) as the most significant risk factor. Blood transfusions (15.2%), surgery (22.2%) and sexual contacts (18.9%) were also suggested as major risk factors. A large proportion of cases has unidentified risk factors (14.1%) in this analysis (242).

Prevalence

One prevalence estimate was generated in the Coimbra District of Colombia in 1994 at 0.46% of the population, and is very unlikely to represent the total population (243). Another study of 131 124 blood donors found an overall prevalence of 0.9% using a second-generation test (244). Lower prevalence was observed in the north (0.68%) than that in the central region (1.0%) or the south (1.59%). The same study also reported HCV prevalence in IDUs between 70 and 92%. Consistent with IDU as a significant transmission factor, notified cases of HCV infection to the Ministry of Health from 1993 to 1997 were the highest in 15–34 year olds, with a male-to-female ratio of 4:1. A national prevalence of 1.5% was estimated by the authors (244).

Diagnosed/incidence

The incidence rate reported by ECDC was 0.9/100 000 in 2005 (10). A general downward trend in incidence rates over time was suggested for Portugal, with a peak in 1998 at 6.9/100 000 person-years declining until 2003 to a rate of 0.7/100 000 person-years.

Genotype

Three reports are available describing the genotype distribution in Portugal (242, 245, 246). Areias et al. provide the most robust and representative sample available; however, no subgenotyping of HCV infection was carried out. Genotype 1 was the most prevalent genotype (52.2%), followed by genotype 3 (34.0%). Genotype 4 was recorded in 7% and genotype 2 was seen at the smaller proportion of 2.4% (242). Smaller studies also suggest that genotype 1 is the most prevalent genotype (71.4 and 59.3% respectively) (245, 246).

Summary

Epidemiological data in Portugal were limited and in some cases dated. Higher prevalence of genotype 3, the age distribution of newly reported cases and a single risk factor study are suggestive of continued transmission by IDU. However, further epidemiological analyses are warranted for Portugal.

Romania

Preliminary data from a nationwide cross-sectional survey conducted from 2006 to 2008 provide the best data for the prevalence and risk factors of HCV in Romania. National screening guidelines are not in place.

Risk factors

The causes of HCV infection have varied over time in Romania. Before1989, the majority of infections was caused by blood transfusions and contaminated medical equipment. Currently, other percutaneous routes (such as IDU) are thought to contribute to a greater portion of infections (247).

In one study of patients in Romania, percutaneous transmission was suggested to be the main route of infection, accounting for 85.9% of cases out of 461 infected patients. Among percutaneous routes of transmission, the following breakdown was reported: bleeding dental procedures (77.3%), general surgery (58.2%), blood transfusion (34.8%), beauty salon visits (18.5%), injections under poor conditions (17.8%), tattoos (5.4%), piercing (4.1%), intravenous drug administration (1.1%) and haemodialysis (0.2%). Non-percutaneous routes were identified in 8.9% of patients, and 5.2% were thought to be community-acquired infections (248). Other studies have also identified percutaneous routes as a major source of infection, attributing transfusions and contaminated medical equipment as likely causes of infection (249–251).

Prevalence

Recent studies on the prevalence of HCV infection in Romania are scarce. Many have focused on blood donor populations (252–254), with a range of 0.3–4.9%. However, studies conducted in this population are not reflective of the general trends in the country. Blood donors in Romania are compensated and screened for a variety of infections and therefore are likely to have a lower prevalence of HCV infection (247).

The overall prevalence in the general population of Romania is 3.5% according to preliminary results of a community study (251). In this study, HCV prevalence was determined for 8039 healthy adults, ages 19–69 years old, from 54 centres spanning all areas of the country. This study also reported a higher prevalence in rural areas compared with urban areas (4.43 and 2.76% respectively), as well as in older age groups, and in those with lower education and income levels (251). The difference in the rural and urban areas may be attributed to educational level and medical practices (247). This study also suggested a significant regional variation, ranging from 0.56 to 7.19% between counties, as well as by age, ranging from 1.5% in the 19–29-year age group to 6.49% in the 60–70-year age group (247).

Two other community studies were performed in the early 1990s. A report published in 1994 found a prevalence of 4.9% in a multidistrict study in the area of Transylvania (255). From a 1990 study of the city of Bucharest, the prevalence rates for multiple groups were ascertained. Out of 100 low-risk adults, 4.5% were found to be positive for anti-HCV antibodies (256).

Genotype

The most common genotype reported in Romania is genotype 1. This result is confirmed in a study by Grigorescu et al., which found 93.46% of 153 patients and 99.13% of 461 patients infected with genotype 1. The most common subtype is 1b (248). Further breakdowns of genotype distribution are not reported by other studies. Currently, the Romanian Health Insurance Agency does not reimburse for genotyping, which may contribute to the lack of genotype distribution studies in the country (250).

Summary

Romania has one of the highest HCV prevalence rates in the European Union (EU), estimated at around 3.5%. The main contributors are blood transfusions before 1995 and the use of incomplete sterilized medical equipment before 1989. After the Communist Era, the main cause of transmission was through percutaneous routes. A 2008 study indicated a large difference in prevalence between counties (0.56–7.19%) and age groups (1.5% in youth to 6.49% in elderly). These data suggest that the HCV prevalence in the young Romanian population born after 1990 is below 1.5%, and there may be a tendency towards decreasing prevalence in future years.

Russia

In Russia, morbidity rates for acute and chronic HCV are reported by the Ministry of Health annually; there has been mandatory registration of newly diagnosed cases for CHC since 1999 and for acute hepatitis C since 1992–1993. Other epidemiological information on HCV is derived from regional or local studies, showing local variances, making extrapolation to the national level difficult. A national screening policy is in place, but does not cover all the cases in the country. Specific subgroups are screened on a regular basis including blood donors, pregnant women, prisoners, haemodialysed patients, drug users starting weaning programmes, healthcare workers and others (257).

Risk factors

Detailed risk factor analysis for HCV transmission was the focus of few studies. It has been suggested that one of the main routes of transmission in the younger population is IDU (258). This corresponds to the results of a study of 46 HCV-positive blood donors, where drug addiction was the only risk factor identified to be significant in males younger than 30 years old, accounting for 35% of the transmission for this age and gender group and 13% overall. Additionally, previous blood transfusion was associated with both genders over 30, accounting for 40% of infections in this age group and 26% of infections overall (259). However, these data are from older workers and small groups of individuals and may not reflect the risk profile for the entire Russian Federation today.

Another study suggested the significance of sexual transmission in sexually abused children, with a difference in anti-HCV detection rates of 8.1% between children with and without reported sexual contact (258). A more recent study examined trends of HCV infection over time. During two 6-year time periods (1995–2000 and 2001–2006), the majority of transmission routes were artificial (IDU, hospital); however, there was also an increase in natural transmission routes (sexual, other contact) during 2001–2006. IDU transmission varied over time in Moscow, potentially accounting for 39.5–56.4% of infections from 1994 to 2001, decreasing slightly in 2002–2004 (20.5–30.1%), and further decreasing in 2006–2007 (16.5–18.6%). Vertical transmission accounted for infections in 0.2–1.3% of children. Many cases had unknown transmission routes: 13.3% during 1994–2000 and 30.6% from 2001 to 2006 (260).

Prevalence

Many Russian studies focus on prevalence rates among blood donors, reporting a wide range of values ranging from 0.93 to 2.5% (259, 261–267). Other studies report on specific subpopulations such as children, pregnant women or rural villages (262, 263, 268, 269).

A study testing 2217 blood samples from former USSR regions found a prevalence of 1.3% in Moscow, 3.0% in Tuva and up to 5.3% among the population of the republics of Central Asia (270). In another study, out of 4216 individuals living in various parts of Russia and Mongolia, a prevalence of 2% was recorded in the European part of Russia (0.7–3.8% depending on the region) and a prevalence of 2.5% was recorded in the non-European part of Russia (2.4–2.7% depending on the region) (271). However, samples for this study were taken from students, voluntary blood donors and healthy adult volunteers and likely represent a lower bound for the actual prevalence in this region. Another study looked at a random sample of 374 adults, aged 25–64, from Siberia, and compared this with blood donors from the same region. The adult general population was found to have a prevalence of 2–2.5 times that of the blood donor population (5.3 and 2.1% respectively). In addition, school-aged children (14–17 years old, n=423) were found to have a prevalence of 2.6% (262). Kuzin et al. (263) have reported trends in the general population in the city of Vladimir, with findings that suggest a gradual increase in HCV infection with age. A study of volunteer blood donors from the Russian Republic of Daghestan found similar trends, with prevalence peaking in the ages over 50 years (259). Data from Moscow also indicated a prevalence rate in adults twice as high as in children (270).

Among community samples, the study by Iashina et al. (270) provided the most extrapolative estimate for prevalence in Russia, ranging from 1.3 to 3.0% in European regions and in excess of 3% in non-European regions. This and other studies indicate that there may be a significant regional variation in Russia. Finally, trends in acute and chronic cases have also been reported to differ. In one analysis, the prevalence of acute cases had decreased over the past decade in Russia, mainly consisting of adults aged 15–39 years (averaging 86.4% of acute cases). Conversely, chronic HCV prevalence had increased, with a majority of the cases in adults aged 20–40 years (260).

Diagnosed/incidence

Reports of incidence indicate rapidly increasing numbers of new infections. According to the Ministry of Health, incidence increased from 3.2/100 000 persons in 1996, to 9.1/100 000 persons in 1997 and 11.6/100 000 persons in 1998 (272). Other sources indicate even greater increases after 1998, with an incidence of 19.3/100 000 persons in 1999 (258). More recent data from the Ministry of Health indicate that the incidence has almost doubled 10 years later, reporting a rate of 40.79/100 000 persons in 2009, with 57 966 cases of CHC that year (273). Another report suggested the incidence of CHC to range from 0.07 to 75.3/100 000 persons and the incidence of asymptomatic carriers to be between 17.2 and 198/100 000 persons (274).

Genotype

Several studies have reported on the genotype distribution of HCV in Russia (275–278). The most robust sample included a total of 562 chronically infected patients. Genotype distribution was as follows: 1 (55.7%), 2 (8.2%), 3 (35.1%) and mixed/other (1.1%). Of these patients, 54.8% were subtype 1b, followed by 3a, which was found in 35.1% of patients (277). Similar results were reported, with genotype 1b most frequently found among 388 infected individuals (50.3%), followed by genotype 3a (44.8%) (275). Other studies with smaller sample sizes also suggest that 1b is the most frequent subtype found in Russia (263, 279).

Summary

Hepatitis C virus infection has been increasing steadily over the past 10 years in Russia, with an incidence of 40.79/100 000 individuals in 2009, according to the Ministry of Health. Prevalence estimates from community studies vary significantly by area, suggesting regional variation within the country. The country risk factor profile may vary over time, with some studies suggesting an increase in the proportion of cases transmitted through natural routes such as sexual transmission or other types of personal contact. Additionally, while IDU has continued to be a major source of transmission, it has accounted for a smaller percentage of cases in Moscow in recent years.

Spain

National surveillance of newly diagnosed cases of HCV is conducted on a voluntary basis in Spain. National screening guidelines are not in place. Aside from a genotype study spanning multiple regions (280), the large body of epidemiological research in Spain has been conducted at the local or the regional level.

Risk factors

The identification of risk factors in Spain arises from five studies (281–285). One study reported hospital admission among 65% of acute cases of HCV infection. Ten per cent of the cases in the study were linked to IDU (281). Another study provided an estimate for prevalence of transmission also among acute HCV cases. Hospitalizations were the most prevalent risk factor (72%), followed by IDU (10%) (282). The fact that these studies were performed in referral centres and the low access of IDUs to the Health Care System may have underestimated the role of drug abuse as a cause of acute HCV infection. Prospective data in the context of a tertiary care centre confirm nosocomial transmission in a hepatology ward, although this estimate is based on small numbers of transmission (286). Patient-to-patient transmission was demonstrated in this study by phylogenetic analysis of isolated HCV. There have been two large epidemiological studies in Spain, representing chronic cases of HCV infection. One study reported in retrospective questionnaires that hospital admission (74.5%), dental-related procedures (85.1%), use of syringes (61.7%) and previous surgery (59.5%) were the most frequent risk factors (284). On occasions, several of these factors coexisted together, suggesting that the use of unsafe syringes or medical procedures was an important factor. The other study showed that tattoos (OR: 6.2), blood transfusions (OR: 5.0), intravenous drug use (OR: 4.9) and antecedents of hospitalization (OR: 2.3) were variables associated independently with infection (285). In a population of northern Spain, parenteral drug addiction predominated among those of the fourth decade, while transfusion and surgery predominated in people over 60 years of age (287). Martinez et al. (283) only analysed genotype 4 patients.

Prevalence

Hepatitis C virus prevalence estimation comes from the literature dating to 1992. However, no population-based estimate is available since 2002. The most recent, and likely best, prevalence estimate comes from a study performed in 2002, where a prevalence of 2.64% in adults 25 years of age or older was reported, with no differences in prevalence between genders. Prevalence was reported to be the highest in individuals over 50 years of age, probably related to syringes and unsafe medical procedures and hospital-based transmission (284). Two further studies reported a prevalence of 2.5 and 1.6%, respectively, in 2001 (285, 287). All three estimates suggest an increased prevalence with age. A community-based survey in Zamora (west central Spain) estimated a lower prevalence of 0.74% in 2002 (288). In a European-wide review of overall prevalence, authors assumed that 2.5% of the total population was infected (6).

More recent studies of pregnant women likely represent a self-selected population (289–291), and are likely lower than the total population prevalence. A 1997 estimate including workers of the National Electricity company suggested a 2.4% prevalence estimate (292), whereas a community-based study from Gijon in 1997 presented an estimate of 1.7% (293). Older estimates were not considered for use in our analysis (294–307).

The prevalence among IDUs has been reported to be over 80% in all but one of the studies reviewed (308–313).

Diagnosed/incidence

The best available incidence was reported at 2.3/100 000 persons in 2003 but was based on voluntary reports rather than mandatory reporting (282). Reports to ECDC coincide with this report (10). Incidence trends over time estimated by the ECDC suggest a decline in overall incidence from 1997 to 2005 (range 2.8/100 000–0.6/100 000 persons), likely because of improvement in historical risk factors like blood transfusions and other peritoneal sources. The ECDC estimate showed a modest increase for 2006 at 1/100 000 persons (10). It was estimated that 140 000 individuals had been diagnosed as of 2004 (107).

Genotype

Several studies reported HCV genotype 1 as the most common (280, 314–317). The three most recent and sufficiently powered studies report remarkably similar results. Genotype 1 was found in 64.1–68.3% of the total cases while genotype 3 accounted for 18.5–20.9% (280, 314, 315). The best estimate is derived from Echevarria et al. (280) with the following genotype distribution: 1 (65.4%), 2 (3.1%), 3 (19.6%), 4 (11.6%) and 5 (0.3%). This study contained 3015 samples from 17 regions throughout Spain, all tested in a single laboratory.

Summary

The prevalence of HCV in Spain is among the highest in Europe. Historically, transmission has occurred through hospital-based sources or the reuse of needles. No definitive, recent study estimate for the overall incidence or prevalence is available. High rates of genotype 3 suggest a continued role of IDU, which is also confirmed by high rates of HCV positivity among IDUs. Increasing rates of genotype 4 have been linked to IDU and immigration (280, 315).

Sweden

Mandatory reporting of both acute and chronic cases of HCV since 1990 provides robust data for incidence, prevalence and risk factors in Sweden. Both the clinician and the laboratory are required to report any HCV infection to the Swedish Institute for Infectious Disease Control (SMI) (318). Since 2007, there has been a national screening effort to identify HCV infections due to blood transfusions (before 1992) by offering and recommending free HCV-tests for everyone who have had a blood transfusion. In addition, drug addicts are screened for HCV infection when they seek therapy for their addiction.

Risk factors

Injection drug use in Sweden is the predominant risk factor. The gold standard reference, reporting data from the national database of communicable diseases with all diagnosed and notified HCV-infected individuals in Sweden, reported that the most probable route of transmission was former or ongoing IDU, accounting for 65% of infections. Following IDU, transfusion of blood or blood products (6%) and sexual contact (2%), were the most common risk factors. Still, in a large proportion of cases, the transmission route was unknown or not stated (318), although a more recent study demonstrated that a high percentage of those with unknown route of infection had been hospitalized because of drug related conditions (319). An earlier study had reported a strong observational association with IDU, followed by blood transfusions, tattoos, previous hospitalizations and a history of sexually transmitted disease (320).

Prevalence

The prevalence of HCV infection has been reported in five studies since 1994 (318, 321–324). Unlike other countries in the EU, post-1990 mandatory reporting of HCV has allowed the nationwide detection of HCV prevalence for Sweden. In 2008, the nationwide prevalence was estimated 0.5%, based on all reported cases to SMI (318). This prevalence rate is supported by a more recent study that linked the notifications to other registries and took into account the number of deaths and emigration (319). By the end of 2006, there were 43 000 reported individuals but only 35 000 of them were alive, resulting in a prevalence of 0.4% with a diagnosed HCV-infection. Assuming 20% undiagnosed infections, the overall prevalence was 0.5%. In the original study, females comprised only 30% of the total HCV infections, while males made up the remaining 70%. Anti-HCV-positive cases in children are rare; hence, the prevalence in the adult population is slightly higher than the overall prevalence (0.59%). Another study used a large, although regional, approach from southern Sweden and reported a prevalence of 0.37%, similar to SMI data (322).

Diagnosed/incidence

True incidence data were not available in the literature. However, the mandatory reporting policy does provide the number of cases reported to SMI. A height of reported HCV cases was seen in 1992 followed by another peak in 1997 (52.1/100 000 persons), with a general decrease through 2005 (29/100 000 persons) (10). In absolute terms, the incidence of reported cases for Sweden is an order of magnitude larger than the estimates seen throughout other parts of Europe, particularly southern Europe due to the presence of a longstanding national mandatory reporting policy. The median age of diagnosis confirms the role of IDU, as 84% of new infections were notified before the age of 50 (318). The 2006 and 2007 incidence rates from ECDC reports suggest an overall incidence rate of 21.8 and 23/100 000 persons respectively (11, 325). Approximately, 80% of the HCV infected population was already diagnosed by 2006.

Genotype

A number of studies have estimated genotypes for populations in Sweden (320, 326–329). The most recent and best report estimated the genotype distribution at 1 (45.2%), 2 (19.3%), 3 (33.8%) and 4 (1.7%) (326). Similarly, another study estimated genotype 1 as the most prevalent genotype in Sweden, accounting for 41% of all HCV-positive individuals (328). In another small study, a similar genotype distribution was observed (320). Another study based on hepatocellular cancer groups showed a higher frequency of genotype 1 (327). All studies indicated a significant portion of the population affected by the 1a subtype (24–57%).

Summary

Sweden has a comparatively low prevalence in Europe. Historical parenteral infection is clearly evident in the increasing prevalence patterns in older cohorts. An exceptional reporting system also contributes to a high case identification rate. The mandatory reporting system Sweden uses allows for arguably the best data collection in all of Europe.

Switzerland

Reporting of positive tests for HCV has been mandatory in Switzerland since 1988, providing national estimates for incidence and routes of transmission. Additionally, the Swiss Hepatitis C Cohort Study (SCCS), a large population-based cohort study consisting of confirmed anti-HCV-positive individuals from all regions of the country, provides robust epidemiological data at the population level (330).

Risk factors

The SCCS has provided the most comprehensive and robust data on the risk factors of HCV transmission for the Swiss population (330, 331). The study has been enrolling patients, aged 18 or older, from the year 2000. Through June 2010, there were 3623 patients enrolled. The study protocol allowed for the selection of more than one risk factor, and for some patients, multiple risk factors were reported. More than half of the patient population identified IDU, which was the most commonly reported risk factor. Reported risk factors were as follows: IDU (57%), invasive medical procedures (35%), blood transfusion (23%), sex with HCV-infected partner (13%), accidental needle-stick (10%), occupational exposure (7.6%) and household contact (5%). The Swiss Federal Office of Public Health (FOPH) data also indicate IDU as the most frequently reported risk factor, among 58% of patients (330, 332).

Prevalence

There are a number of Swiss studies that have addressed HCV prevalence in specific high-risk subgroups such as IDUs (333–337). Others found high rates of anti-HCV-positive individuals in patients visiting an emergency room, dialysis patients, organ donors and lymphoma patients (338–341). Conversely, a very low prevalence (0.095%) was reported in dental workers, although the authors indicated that population biases were likely (342). Studies on blood donors demonstrated a prevalence of <1% (341, 343). One robust study measured prevalence in pregnant women (344). 9057 women with consecutive births from obstetric wards in public hospitals from 23 of 26 cantons in Switzerland were enrolled from 1990 to 1991. In these women, aged 15–58, the anti-HCV prevalence was 0.71%.

However, there are no community-based prevalence studies in Switzerland. Therefore, the FOPH relies on the studies completed with pregnant women and blood donors to estimate the prevalence in the general population between 0.5 and 1%. However, as we have seen in other countries in this report, studies in pregnant women and blood donors underestimate the true prevalence in the general population. The estimate provided by Sagmeister and colleagues is probably more representative of the true prevalence in the country. This study used FOPH reported cases and prevalence estimates and future disease burden assumptions to model a prevalence range of 1.25–1.75% (345).

Reporting of positive tests for HCV has been mandatory in Switzerland since 1988. Positive tests are reported to the FOPH, which cross-checks for duplicate reporting. In summary, males represented more infections than females at a ratio of 3:2. Also, age-specific prevalence rates increase to age 20, remain high until age 44 and then decline (330, 345).

Diagnosed/incidence

The newly diagnosed cases of HCV reported by the FOPH provide an estimate of incidence for Switzerland. With the exception of 2009, there has been a decline in the number of new cases annually since 2002. As of 24 October 2010, 1224 new cases of positive HCV serology have been reported to the FOPH (1300 in 2009; 1291 in 2008). As of June 2010, 3623 anti-HCV-positive individuals have been enrolled in the SCCS, which would suggest a diagnosis rate of 4%. However, others reported a diagnosis rate of 14% in 2002 (344). The estimated incidence of acute HCV (per year and 100 000 inhabitants) based on the declared cases was 1.2 in 2009 and 0.6 in 2008 (estimated incidence for 2010: 0.8) (332, 346).

Genotype

The Swiss HCV Cohort Study offers the most definitive source for genotype distribution in Switzerland (330). Genotyping was available for 2207 patients through 2005, with genotype 1 (51%) and genotype 3 (30%) the most prevalent. Genotype 2 was represented in 9% of patients and genotype 4 in 10% of patients.

Summary

As of June 2010, 3623 anti-HCV-positive individuals have been enrolled in the SCCS and 3356 (92.6%) were viraemic. The HCV-infected population in Switzerland is characterized by a significant immigration rate, foreign-born persons accounting for about one-third of the total number of patients enrolled in the Cohort (1149, i.e. 31.7%) (346). For comparison, foreign residents in Switzerland were 21.7% of the general population in 2009 (347).

Despite this, the number of new infections reported each year to the FOPH has been declining steadily since 2002 by about one-third, from approximately 2500 declarations to the current 1600. This may, however, suggest lack of efficient case identification in populations of patients not usually considered at high risk of infection.

Turkey

Turkey is lacking a national screening or reporting system for HCV. The epidemiological picture of HCV in Turkey is derived from local or regional studies, which indicate potential geographic differences, making extrapolation to the national level difficult.

Risk factors

A small number of studies identified the risk factors for HCV infections (348–351). A prior history of blood transfusion was identified as a key risk factor in multiple studies (348–350). However, it is unlikely to be a source of new infections, as Turkey began testing for HCV in blood donors in 1996. In an academic hospital in Istanbul, 38.8% of the HCV-infected cohort described a history of transfusion before 1996 (350). Nosocomial risk factors (e.g. history of hospitalization, surgery, dental procedures) are reported for the majority of HCV cases (348–351), while IDU accounted for a very small number of HCV cases (4% or less) (348–350).

Prevalence

Based on the available data, the current best estimate for the prevalence is approximately 1.0%. In a recent randomly selected, large population-based study (n=5471), the prevalence was 0.95% in an adult population 18 years of age or older (352). In a community-based study of 2852 randomly selected individuals, a prevalence rate of 1.0% was recorded (348). Other recent, randomly selected population-based studies report varying estimates of the prevalence across Turkey, from 0.6% (353) in 2888 individuals in the southeast to 2.1% (354) in a study of 1095 individuals in a region near the Black Sea, which may suggest regional differences. Both studies found no significant difference in the prevalence for those living in rural vs. urban areas (353, 354). Other studies reflect the range of prevalence estimates that have been reported in blood donors (0.19–0.68%) (355–361), in patients during routine outpatient visits (2.2–2.4%) (351, 362) and in a less recent population-based study (1.5%) (363).

Prevalence studies of blood donors have lower prevalence rates than the community-based studies. In 44 982 blood donors, a prevalence of 0.35% was reported (356), similar to that found (0.38%) in 6 240 140 blood donors from 1989 to 2004 (357), and in 29 049 blood donors (0.37%) (359). A slightly higher prevalence was reported in 11 234 Turkish soldiers who donated blood in Cyprus (0.46%) (360), while a slightly lower prevalence was reported in 37 886 blood donors from 1993 to 2002 (0.19%) (361).

The prevalence in patients tested during routine outpatient visits was higher than that in the community-based studies. A prevalence of 2.2% was reported in a study of 1320 patients during routine check-ups (362). A prevalence of 2.4% was observed in 1157 patients seeking treatment at an outpatient clinic for various reasons, including testing for HCV (351).

Studies in subgroups also found varying prevalence rates. A study of 302 women of childbearing age found a prevalence of 8.9% (364). The authors hypothesize that the relatively high rate may be attributed to iatrogenic transmission via non-hospitalized childbirth or invasive dental procedures. Another study of 4700 pregnant women indicated a prevalence of 0.1% (365). A study of 1332 engaged couples found a prevalence of 0.1% (366). Another study found a prevalence of 2.5% in 227 elderly individuals living in nursing homes (367).

There are differences reported by gender. Three studies reported no differences in rates by gender, although in general, males had slightly higher rates. The reported rates in males were 0.8, 2.5 and 6%, and the rates in females were 1.1, 2.0 and 5% respectively (348, 353, 362). Erden et al. (351) reported higher prevalence in males (3.7 vs. 1.9%), while Yildirim et al. (354) reported a higher prevalence in females (2.5%) compared with males (1.7%), which may indicate regional differences in the gender rates between Istanbul and Tokat.

Genotype

Genotype 1b is the most prevalent genotype in Turkey, with estimates ranging between 75.3 and 90% (349, 360, 368–370). The most recent estimates of genotype distribution come from a study in 345 patients with chronic HCV infection, and indicated that nearly all of the genotypes of HCV in Turkey are genotype 1 (97.1%), with genotype 1b as the major subtype (87.2%), followed by subtype 1a (9.9%), genotype 3 (1.4%), genotype 2 (0.9%) and genotype 4 (0.6%) (368). A study in 2004 in 365 persons found similar results, showing genotype 1 as the major genotype (95%), with genotype 1b as the major subtype (84%), followed by subtype 1a (11%), genotype 2 (3%), genotype 3 (1%) and genotype 4 (1%) (369). In 53 Turkish soldiers living in Cyprus, genotype 1b (97.1%) and 1a (2.3%) were the most prevalent (360). An analysis of Turkish patients who have lived in Europe for between 5 and 39 years and those who live in Turkey found a difference in subtype prevalence (349). In those who had lived in Europe for an extended period of time, genotype 1a was most prevalent (60%), followed by genotype 1b (20%) and 3a (20%). In those who lived in Turkey, genotype 1b was most prevalent (90%), followed by genotype 1a (10%) (349).

Summary

Overall, Turkey has a low prevalence of HCV infection, estimated to be around 1.0%. This is primarily because of the low rate of IDU and the early introduction of screening of blood donors. There may be regional differences in prevalence within Turkey, with higher rates reported in regions near the Black Sea compared with southeastern Turkey, although this varies between studies. The majority of chronic infections are genotype 1b, with estimates ranging between 75 and 90%.

UK

In 1990, the Health Protection Agency Centre for Infections in England and Wales (HPA) implemented a voluntary reporting system for laboratory-confirmed cases of HCV (371). Health Protection Scotland (HPS) also collects and reports the number of newly diagnosed cases of HCV infection annually (372). Additionally, both the HPA and the HPS have collected data on routes of transmission and genotype distribution throughout the UK. Both health agencies have also conducted thorough analyses of the epidemiological literature for their prospective countries and modelled the natural history of HCV infection to arrive at prevalence estimates for England, Wales and Scotland.

Risk factors

Approximately 20% of laboratory-reported cases in England and Wales from 1996 to 2007 (n=11 520) included information on risk factors (371). In excess of 90% of cases listed IDU as the risk factor for acquisition for infection, mostly males between ages 25 and 44. The reported risk factors included IDU (92.5%), transfusion (1.6%), blood products (0.9%), sexual exposure (1.4%), renal failure (0.6%) and vertical or household transmission (0.3%).

Similarly, HPS collects epidemiological data on individuals diagnosed with HCV in Scotland (373). Risk factor information was available for 12 522 persons (67% of all diagnosed) through 2004. Again, IDU was the most predominant risk factor, encompassing 90% of individuals reporting. Other reported risk factors were blood transfusion/blood products (5%), and occupational, tattoos, body piercing or sexual contact (5%).

Prevalence

The HPA in England and Wales created a model taking into account prevalence data from multiple population segments to estimate prevalence for HCV in the general population (371, 374). Population segments considered include IDUs, pregnant women, blood donors and anonymous serum specimens from Genitourinary Medicine clinics. Since 1986, the HPA has collected residual serum specimens for investigating the prevalence of many diseases, including HCV. The HPA's Bayesian model concluded that in 2003, there were 191 000 anti-HCV-positive individuals, aged 15–59, in England and Wales. This corresponds to a prevalence of 0.6% for this age cohort.

Similarly, HPS has undertaken a meta-analysis of published reports of HCV prevalence in various populations in Scotland (373). HPS estimates a prevalence of 1% for all of Scotland's population. As of 2006, 38 000 living people in Scotland were estimated to be infected with HCV (375).

A large number of studies demonstrate an elevated prevalence rate in the IDU population (376–386). Prevalence rates for pregnant women, blood donors, specimens gathered from clinics, as well as healthcare workers are represented in several studies conducted throughout the UK (382, 387–398).

Diagnosed/incidence

The ECDC reports the incidence of reported HCV cases for the UK (10, 11, 325). Although there is some variation in rates from year to year, incidence remains below 20/100 000 in this decade.

Laboratory-confirmed diagnoses of HCV infection are received from all regions in England by the HPA (371). From 1995 through 2007, a total of 59 938 cases, or 36% of the prevalent population, were diagnosed. There has been an increase in diagnosed cases annually almost every year during this time span, with 7540 reported cases in 2007. HPS also reports on an annual basis the number of newly diagnosed cases of HCV infection. In 2009, there were 2013 reported cases (372). As of 2006, 14 500 individuals, or 38% of the infected population, were already diagnosed in Scotland (375).

Genotype

The HPA implemented a Sentinel Surveillance Study of Hepatitis testing in 2002 to enhance routine surveillance of HCV (371). Twenty-three sentinel laboratories across England participated, providing laboratory test results and demographical data for all individuals tested. As part of a more focused review, genotype distribution and trends data from 10 sentinel laboratories were analysed. Using data from 2002 through 2007, 18 440 samples provided genotyping. Collectively, genotypes 1 and 3 represented 85% of all HCV disease in England. Specifically, the genotype distribution was as follows: 1 (45%), 2 (10%), 3 (40%) and 4 (5%). Although with smaller cohorts and more distant timeframes, other authors found remarkably similar results in genotype distribution in English populations (399, 400). Reported data from HPS and confirmatory testing laboratories in Scotland indicated a similar distribution in the Scottish population, specifically genotypes 1 (47%), 2 (5%) and 3 (47%) (373).

Findings from the Sentinel Surveillance of Hepatitis Study indicated that genotype 3 increased from 42 to 47%, and genotype 1 decreased from 45 to 42%, over the study time period (2002–2007) (371). Findings from all studies, indicating a high proportion of genotype 3 cases, are consistent with the risk factor distribution in the UK, which is heavily weighted to IDU.

Summary

Overall, the UK is considered an area with a relatively low prevalence of HCV infection (0.6–1.0%) depending on the region. New HCV infection in the UK is driven by IDU, the dominant risk factor stated in all the reviewed studies. The high prevalence of drug use in the UK will continue to drive up the prevalence of HCV for the foreseeable future unless or until effective prevention strategies are developed and implemented. It is important to recognize that IDU as a risk factor for acquisition of HCV does not equate to problem drug use. The highest risk of HCV infection is early in experimentation with drugs, where sharing ‘works’ is more common and there is limited exposure to harm reduction messages. There is no reliable evidence about the proportion of individuals who have used injection drugs at least once, who go on to become registered with a drug addiction treatment service. Many, if not the majority, of these individuals never develop a medically recognized drug problem. However, all the estimates of HCV prevalence are based on the size of the drug-using population and are derived from the numbers attending drug problems services. Thus, while the prevalence of HCV infection is high in drug problem treatment centres, probably the majority of those infected with HCV are not in such locations. Given the natural history of drug use in the UK, there is a large cohort of undiagnosed patients unaware of HCV or their infection with it, whose duration of disease places them at a high risk of developing cirrhosis or hepatocellular cancer. Another important factor in the HCV epidemic in the UK is the impact of immigration from countries with political and historical links to the UK, in particular former Eastern European countries and Pakistan, both areas of high endemicity. Given that drug use and areas of residence of immigrants are not uniformly distributed across, then we can assume that HCV infection is not uniformly distributed, with areas of high prevalence focused in cities, particularly in more deprived areas. Adding the problems of deprivation to the disease burden of HCV makes access and treating those affected by HCV even more difficult.

Discussion

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Epidemiological data on HCV prevalence and risks factors for transmission are important to implement measures for prevention and HCV screening. Comparison of epidemiological data over time may allow some conclusions about the change of risk behaviours and the success of existing prevention or screening programmes.

We provide a comprehensive review of HCV epidemiology throughout Europe, Canada and Israel. The available data indicate a wide variation in HCV prevalence (Fig. 1) and differences in HCV transmission between countries. Prevalence data differences and dynamics within and between countries may sometimes be explained by local and regional variances in transmission routes or different public health measures. The lowest HCV prevalence (≤0.5%) estimates are from northern European countries, and the highest (≥3%) are from Romania and rural areas in Greece and Italy, as well as portions of Russia.

image

Figure 1.  Hepatitis C virus prevalence and genotype distribution in Europe, Canada and Israel.

Download figure to PowerPoint

Also, different surveillance systems among different countries may contribute to the varied findings. A publication by ECDC documented 38 different surveillance systems in 27 countries; six countries had more than one system (10). Surveillance systems vary by structure, reporting practices, data collection methods and the case definitions used (11), leading to variance in completeness and representativeness, which must be considered.

The true prevalence is likely to be higher since general population studies exclude high-risk subgroups like active IDUs, homeless, incarcerated and veterans. The HCV infection rate is substantially higher in these subgroups as illustrated by a recent study that showed that HCV prevalence among prisoners in Spain was 22.7% (401). Studies have shown that the overall prevalence is higher than national estimates when these subgroups are considered (402, 403).

We have to acknowledge that HCV prevalence describes, in most cases, anti-HCV positivity, which is not the same as the prevalence of chronic HCV infection. Fifteen to 50% of patients with acute HCV infection show clearance of HCV spontaneously (404–407). Thus, the exact prevalence of patients with chronic HCV is 15–50% lower. An exact number of HCV-infected patients is not possible. However, we estimate that 11.3–14.7 million adults in Europe, including all of Russia and Turkey, are anti-HCV positive.

Injection drug use has become the main risk for HCV transmission in countries with well-established HCV screening programmes of blood products and lower HCV prevalence. For example, in northern European countries such as Norway and Sweden, or in UK or Canada, IDU is the main risk factor for HCV transmission, accounting for more than half of HCV-infected patients (i.e. Norway 67%, Sweden 65%, Canada 58% and UK 90%).

Injection drug use as the main risk for HCV transmission is associated with some other findings such as younger age at the time of infection (i.e. HCV incidence peak in Canada 25–29 years (12)). Many studies in areas with IDU being the main risk factor for HCV transmission reported a higher male-to-female ratio in HCV-infected patients (i.e. 70% in Sweden). This may be explained by different risk behaviours between the genders. IDU is more frequent among males than females (54). However, a different male/female ratio can also be explained by other reasons. For example, MSM are at risk for sexual HCV transmission (408, 409). Spontaneous HCV clearance may occur more frequently in females because of an improved immune response (407). Interestingly, some reports from countries with low IDU prevalence show higher HCV prevalence in females. This may be explained by transmission via blood products (221).

Also, the distribution of HCV genotypes may be related to different routes of transmission, such as IDU. HCV genotypes 1a and 3 are associated with IDU-related infections, whereas HCV genotype 1b is related to transmission via blood products (6). Consistent with this suggestion, HCV genotypes 1a and 3 are more frequent in countries where IDU is the main reason for HCV infection (Table 3).

Table 3.   Availability and quality of hepatitis C virus epidemiology data by country
 Risk factorsPrevalence rateGenotype distributionIncidence rateDiagnosis rate
  • Some of Canada and UK's data are based on an epi model rather than a general population study. Three stars were given for each given the robustness of the model.

Canada********************
Czech Republic******  
France******************
Germany***********************
Greece************* 
Hungary********* 
Israel**************
Italy************* 
Norway************** 
Poland*************
Portugal******** 
Romania***********  
Russia*********** 
Spain**************
Sweden**********************
Switzerland**********************
Turkey*********  
UK**********************

In some countries with increasing HCV prevalence over the last few years, the increase may be explained by a dramatic increase in IDU. For example, IDU was less frequent in former communist countries such as Russia, Poland and the Czech Republic, but for the past several years, the prevalence of IDU has exploded. This may help to explain the increasing HCV prevalence rates in Eastern European countries.

In a 2006 study from the Czech Republic, only 30% of IDUs were anti-HCV positive (30), increasing to 50% in a study published 1 year later (29). In line with these data, HCV genotype 1a and 3 prevalence increased from 23 and 3%, respectively, reported in a 2001 study (28), to 40.5 and 23.5%, respectively, reported in 2009 (26).

Although a study suggested that IDU as a risk factor is less important in Poland than in other countries (221), epidemiological data suggest that IDU may account for a significant number of HCV cases in Poland. HCV prevalence is higher in urban areas than that in rural areas. Male/female ratio is high (225), and finally HCV genotype 3 prevalence increased (240). Because HCV incidence has increased from 2000 until 2006, mainly in young males, this suggests an increase in HCV transmission via IDU.

Also in Hungary, we noted an increase in HCV genotype 1a infection, which may be explained by an increase in IDU (139, 140). However, IDU was reported to be infrequent in Hungary (136). In Russia, there has been an increase in HCV incidence over the last 10 years, especially in adults aged 20–40 (260), and some studies report a high prevalence of HCV genotype 3 infection (275, 276). Also in Russia, IDU as a risk factor has decreased in more recent reports, and unknown transmission routes increased to 30.6% (260). The patients may fear consequences when admitting drug use and thus the reported results may be biased. Male/female ratio and change of HCV genotype distribution clearly suggest an increase in IDU over the last few years.

As HCV incidence is still increasing in Eastern European countries, mainly because of an increase in IDU, there seems to be a decline in newly acquired HCV infections in western countries. The decline in HCV prevalence of individuals 20–59 years of age observed in France between 1994 and 2004 may thus be because of effective needle share programmes. For example, IDU as a risk factor for newly diagnosed HCV patients declined from 51% in 1997 to 31% in 2003 (55). Studies indicated that HCV prevalence may have declined among IDUs from 73% in a 2002 sample (410) to <60% in samples from 2004/2005 (37, 61). Also, France has established a comprehensive screening programme, which may be responsible for a decline in HCV prevalence. In a prevalence study, about 57% of anti-HCV-positive individuals already knew about their diagnosis. Importantly, >90% of current or previous IDUs had previously been diagnosed (37). Awareness of HCV infection is one of the most important prevention measures. Also in Canada, it is estimated that two-thirds of the HCV-infected population is already diagnosed (12). The HCV prevalence in Canada has been declining since 1998 (Table 1).

In Germany, the RKI, despite no general screening programme, has observed a yearly decline of approximately 10% per year (87). Methadone substitute programmes and increasing numbers of effectively treated patients may account for this change.

This is important information for all countries with increasing HCV prevalence mainly because of IDU. This may especially be important for the Eastern European countries. The number of active IDUs in the EU alone is estimated to be between three-quarters of a million and 1 million (136). However, detailed data from Eastern Europe are lacking.

Without effective prevention measures, HCV transmission occurs rapidly within the IDU population. Reports have shown that in individuals with not >1 year of IDU, 65% were anti-HCV positive (411). HCV prevalence among IDU patients can be as high as 90% (337). Thus, considering the increasing numbers in IDU, there is an unmet need for effective prevention measures with the IDU population, especially in Eastern Europe.

Countries such as Greece, Turkey and Romania with intermediate-to-high HCV prevalence may face different problems, especially in rural areas of the country. IDU is not yet the main cause for HCV transmission in rural areas with limited medical care. Contaminated syringes account for the majority of new HCV infections (115), resulting in high HCV prevalence rates (i.e. up to 10.9% reported for Crete (125), 7% for rural areas in Romania (247)). The main HCV genotype in those patients is 1b. It is interesting that HCV genotype 1a is more frequent among Turks living abroad (60%), where IDU may be the main risk factor compared with a higher prevalence of HCV genotype 1b (90%) in patients living in Turkey (349). The male/female ratio in HCV-infected patients in Turkey is almost 1:1 (348, 353, 362). IDU is suggested to account for only 4% of HCV-infected patients in Turkey (348–350).

Similarly, some parts of southern Italy show a high HCV prevalence mainly because of intravenous therapies with contaminated glass multi-use syringes (157, 159). And in Spain, hospital admission was among the most frequently identified transmission routes in multiple studies (281, 282). Increasing prevalence with age and no gender difference also indicate a historical basis for the transmission of HCV in these regions. However, a high rate of genotype 3 in Spain (280, 314) and a second prevalence wave identified in urban areas in Italy (201) implicate IDU as the primary risk factor of the future.

In those areas in which nosocomial infections are frequent, it is essential to implement high-quality sanitation protocols concerning equipment sterilization, washing and other hygiene measures to prevent further HCV transmission. However, even in countries with lower HCV prevalence, occupational HCV transmission occurs. For example, a German study analysed the route of transmission in 259 patients with acute HCV infection; 28% had been infected by medical procedures or needle stick injury (90).

Another important issue we have to face is immigration. Because of globalization and historical or political relations to countries with high endemicity, immigration will lead to an increase in the transmission of infectious disease. Immigration is a major issue in Israel, as 70% of current HCV-infected individuals were born in the former Soviet Union (151). In Switzerland, about one-third of the infected population was not born in Switzerland (346). Similarly, a large study from Germany reported that 37% of HCV patients had their origin not in Germany; most of the patients were German repatriates returning from the former USSR (88). In the UK, immigration in particular from countries with historical links and high HCV endemicity (India, Pakistan) has a major impact on HCV prevalence. Immigration will also lead to a change in HCV genotype distribution. An example is a high prevalence of HCV genotype 4 in Greece because of immigration from Africa (113). HCV screening for immigrants from areas with high HCV prevalence may be an option to improve diagnosis rates. It will be important that immigrants have access to the public healthcare system.

There are substantial gaps in the quality of data available across Europe (Table 4). Data on new infections are not available in each country, or the data gathered do not distinguish between acute and chronic infections. There are also little data available on the size of the diagnosed population. There is considerable variability among the type and quality of prevalence studies among the countries assessed. Countries like France, Germany and Romania have completed large population studies, although some were limited to urban populations, while others, like Canada and the UK, relied on modelling high-risk populations to estimate the total infected population size. However, there were also many countries that relied on studies in subpopulations to estimate the total prevalence in the country. Our research should help to identify major gaps in HCV epidemiology data by country and prioritize future research. Because many countries in Europe (e.g. Italy, Portugal, Spain, etc.) lack country-wide prevalence estimates–in part because of differences in healthcare delivery and a nationwide health statistics reporting system for HCV–we agree with ECDC recommendations for a harmonized EU-wide surveillance system. It will be important to implement high-quality surveillance programmes that distinguish between acute HCV infection and CHC. Furthermore, it would be beneficial to acquire data on HCV disease burden in those surveillance programmes. Adequate data will allow comparisons across the region, which will enable more accurate disease prevalence figures for planning purposes in the coming years.

Table 4.   Summary of hepatitis C virus epidemiology data by country
 Top three risk factorsPrevalence rate in the adult populationDiagnosis rate
  1. IDU, injection drug use.

Canada57.7% drug use 10.7% transfusion 0.35% haemodialysis1.01%66.7%
The Czech Republic16% IDU 15% blood transfusion 14% surgery1.5-2.0%
France26% IDU 28% nasal drug use 7% endemic birthplace0.84%57.3% as of 2004
Germany45.5% IDU 17.4% blood products 9.0% medical procedures0.4%38% as of 2004
Greece30% IDU 25% blood transfusion1–1.9%
HungaryNosocomial infection Tattooing IDU0.6%
Israel42% blood transfusion 14% IDU1.96%33% as of 2010
Italy88% glass multiuse syringe use 29.6% sexual contact 27.8% IDU 27.6% blood transfusion5.2%12% as of 2004
Norway67% IDU 6% blood transfusion0.70%
Poland26.8% blood transfusion 13.6% occupational 8.8% IDU1.9%2.7% as of 2006
Portugal58.7% IDU 22.2% surgery 18.9% sexual contacts1.5%
Romania77.3% bleeding dental procedures 58.2% general surgery 34.8% blood transfusion3.5%
Russia26% blood transfusion 13% drug addiction 11% acupuncture/tattooing2.0–2.5%
Spain85.1% dental procedure 74.5% hospital admission 61.7% use of syringes2.64%17% as of 2004
Sweden65% IDU 6% blood transfusion 2% sexual contact0.59%80% by 2006
Switzerland57% IDU 35% invasive procedure 23% blood transfusion1.25–1.75%14%
Turkey38.8% blood transfusion 16.6% surgery 15.7% dental procedure1.0%
UKEngland and Wales0.6%– England/Wales36% as of 2004
 92.5% IDU  
 1.6% transfusion  
 0.9% blood products  
Scotland1%– Scotland38% as of 2006
 90% IDU  
 5% blood transfusion  
 5% occupational, tattoos  
 Body piercing, sexual contact  

In summary, HCV epidemiology shows a high variability across Europe, Canada and Israel. Despite eradication of transmission by blood products, there is still an increase in HCV incidence in some countries. Continuous increase in IDU across Europe, especially in Eastern Europe, and immigration will lead to changes in HCV epidemiology. In countries with surveillance programmes and already established healthcare programmes, we observe a decline in HCV prevalence. Obviously, countries that collect data on HCV epidemiology used this information for implementation of prevention measures. Other countries with still increasing HCV incidence may learn from countries with already established programmes. HCV surveillance is the first step, followed by a country-specific HCV screening programme.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

This study was completed through the International Conquer C Coalition (I-C3) organization. Funding for this programme was provided through an educational grant provided by Merck & Co Inc. and support from the Center for Disease Analysis. We are indebted to all I-C3 and Regional Conquer C Coalitions (R-C3) members for their contributions and comments. We would also like to thank Dr Delarocque-Astagneau of Institut de Veille Sanitaire, Saint-Maurice, France, for helping with ranking of the published work in France. Sona Frankova was funded by IKEM MZ0 00023001. Finally, we would like to acknowledge Regina Klein of Center for Disease Analysis for her assistance with data gathering and analysis in the preparation of this document.

Disclosures: MC received lecture fees and/or consulting fees: Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Novartis, MSD and Roche. Research funding: MSD, Roche. HAR, AL, SS, CW, KY Grant: Merck. AA Consultant: Roche, Gilead, Novartis, BMS, J&J, Merck, Schering-Plough, Research Grants: Gilead, Merck, BMS. EB Nothing to disclose. CC Researcher: Merck, Roche, BI, Vertex, Tibotec and Gilead. Speaker: Merck, Roche. Advisor: Merck, Roche and Vertex. OD No financial interests in any company related to the HCV field. Received fees for services on advisory panels and giving educational lectures from Schering-Plough, MSD and Roche. JFD Consultant: MSD, Gilead, BMS and Novartis. MBF Lecture fees: Roche, MSD, BMS and Gilead. Advisory Board Member: MSD, BMS, Novartis and Pfizer. Grant: Roche, Schering-Plough. Advisor: Merck, Janssen/Tibotec. RF Nothing to disclose. XF Nothing to disclose. SF Advisor: MSD. AG Nothing to disclose. IG Nothing to disclose. WH Nothing to disclose. BH Advisory Board Member: Bristol-Myers Squibb, MSD. Speaker: Roche, MSD, Bristol-Myers Squibb. Research: Roche, MSD and Idera. Nothing to disclose. ML Grant/Investigator/Speaker and Expert: Roche, Schering-Plough and Gilead. Investigator/Speaker and Expert: BMS, Novartis, Tibotec and Intermune. Investigator/Expert: Vertex, MSD and Biolex. Investigator: Boehringer. Expert: Pharmasset, Zymogenetics. MM Advisory Board Member: Merck, Roche, Gilead, BMS, Novartis, Bayer and Abbott. SM Board Member: BMS, Boehringer Ingelheim, Tibotec/Janssen Cilag, Gilead, Roche, Merck/Schering-Plough and Abbott. Speaker: GSK, BMS, Boehringer Ingelheim, Tibotec/Janssen Cilag, Gilead, Roche and Schering-Plough. Grants: BMS, Gilead, Roche and Merck/Schering-Plough. PM Nothing to disclose. RTM Nothing to disclose. SP Member of CEE R-C3 sponsored by Schering-Plough/Merck. Lecture Fees: Schering-Plough/MSD, Roche, GlaxoSmithKline and Bristol-Myers Squibb. TP Advisory Board Member: BMS Poland, MSD and Roche Poland. MP Advisory Board Member: Merck. Advisory Board Member and Speaker's Bureau Member: Roche. OS Nothing to disclose. KS Advisor: Schering-Plough, Roche, Abbott and Gilead. CY Consultant: Abbott, Achillion, Anadys, BMS, Gilead, Itherix, Merck, Novartis, Pfizer, Roche, Santaris, Tibotec and Vertex.

References

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  • 1
    Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011; 9: 718.
  • 2
    Omland LH, Krarup H, Jepsen P, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 3642.
  • 3
    Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9: 34.
  • 4
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 51321.
  • 5
    Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009; 19: 24553.
  • 6
    Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 14862.
  • 7
    Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: a systematic review. Intervirology 2007; 50: 18.
  • 8
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, et al. Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 2002; 40: 16569.
  • 9
    Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total HCV-infected population size – model validation using US data. Liver Int 2011; 31(Suppl. 2): 419.
  • 10
    Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe – a review. Euro Surveill 2008; 13: 18.
  • 11
    European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2009. Report on the State of Communicable Diseases in Europe 2009, Revised Edition. European Centre for Disease Prevention and Control, Stockholm, 2010.
  • 12
    Remis RS. Modelling the Incidence and Prevalence of Hepatitis C Infection and Its Sequelae in Canada, 2007: Final Report. Community Acquired Infections Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2009. Available at http://epe.lac-bac.gc.ca/100/200/301/phac-aspc/modeling_hepatis_c_infection-e/HP40-39-2009E.pdf (accessed 26 March 2011).
  • 13
    Enhanced Hepatitis Strain Surveillance System. Health Canada. Epidemiology of Acute Hepatitis C Infection in Canada. Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS). Ottawa: Centre for Communicable Diseases and Infection Control, 2009.
  • 14
    Public Health Agency of Canada. Evaluation of the Hepatitis C Prevention, Support and Research Program 1999/2000–2005/2006. Ottowa: Public Health Agency of Canada, 2008.
  • 15
    Remis Robert S. A Study to Characterize the Epidemiology of Hepatitis C Infection in Canada, 2002: Final Report/Prepared by Robert S. Remis Computer File. Hepatitis C Prevention, Support and Research Program, Public Health Agency of Canada, 2008.
  • 16
    Zahariadis G, Plitt SS, O'Brien S, et al. Prevalence and estimated incidence of blood-borne viral pathogen infection in organ and tissue donors from northern Alberta. Am J Transplant 2007; 7: 22634.
  • 17
    Manuel DG, Johnson I, Fearon M, Hockin J. The prevalence of hepatitis C in a community-based population, Ontario, 1996. Can Commun Dis Rep 1999; 25: 1939.
  • 18
    Public Health Agency of Canada. Notifiable Diseases Online 2005, 1991–2004. Available at http://dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/c_inda-eng.php
  • 19
    Marotta P, Cooper CL, Wong DK, et al. Impact of advanced fibrosis and cirrhosis on sustained virologic response of HCV G1-infected patients: results of the Canadian power program (Abstract #1216). 58th annual meeting of the American Association for the Study of Liver Diseases, 31 October–4 November 2008. San Francisco, California, USA. Hepatology 2008; 48 (Suppl. 1): 849A.
  • 20
    Antonishyn NA, Ast VM, McDonald RR, et al. Rapid genotyping of hepatitis C virus by primer-specific extension analysis. J Clin Microbiol 2005; 43: 515863.
  • 21
    Chaudhary RK, Tepper M, Eisaadany S, Gully PR. Distribution of hepatitis C virus genotypes in Canada: results from the LCDC Sentinel Health Unit Surveillance System. J Can Infect Dis 1999; 10: 536.
  • 22
    Bernier L, Willems B, Delage G, Murphy DG. Identification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol 1996; 34: 28158.
  • 23
    Murphy DG, Willems B, Delage G, et al. Hepatitis C virus genotypes in patients and blood donors – Quebec. Can Commun Dis Rep 1995; 21: 12932.
  • 24
    Andonov A, Chaudhary RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol 1994; 32: 20314.
  • 25
    Frankova S. Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Screening for hepatitis C in the Czech Republic. Conversation with Largen A, Center for Disease Analysis, Kromite, Louisville, CO, USA, 14 November 2010.
  • 26
    Krekulova L, Rehak V, Strunecky O, Nemecek V. Current situation and trends in the hepatitis C virus genotype distribution among injecting drug users in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58: 849.
  • 27
    Urbanek P, Marecek Z, Brodanova M, et al. Risk factors for transmission of hepatitis C in the the Czech population. Cas Lek Cesk 2002; 141: 1858.
  • 28
    Krekulova L, Rehak V, Madrigal N, et al. Genotypic and epidemiologic characteristics of hepatitis C virus infections among recent injection drug user and nonuser populations. Clin Infect Dis 2001; 33: 14358.
  • 29
    Hobstova J, Vitous A. Infectious diseases of drug users in the Czech Republic. Cas Lek Cesk 2007; 146: 13741.
  • 30
    Zabransky T, Mravcik V, Korcisova B, Rehak V. Hepatitis C virus infection among injecting drug users in the Czech Republic – prevalence and associated factors. Eur Addict Res 2006; 12: 15160.
  • 31
    Nemecek V, Castkova J, Fritz P, et al. The 2001 serological survey in the Czech Republic – viral hepatitis. Cent Eur J Public Health 2003; 11 (Suppl.): S5461.
  • 32
    Klofera M, Chalupa P, Jezek P. Hepatitis C antibodies (anti-HCV) in blood donors at the transfusion department in Brno. Cas Lek Cesk 1994; 133: 45962.
  • 33
    Nemecek V, Strunecky O. Genotypic heterogeneity of hepatitis C virus (HCV) from blood donors in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58: 6372.
  • 34
    Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17: 43543.
  • 35
    Jullien-Depradeux AM, Bloch J, Le Quellec-Nathan M, Abenhaim A. National campaign against hepatitis C in France (1999–2002). Acta Gastroenterol Belg 2002; 65: 1124.
  • 36
    Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997; 25: 14906.
  • 37
    Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010; 82: 54655.
  • 38
    King LA, Le Strat Y, Meffre C, Delarocque-Astagneau E, Desenclos JC. Assessment and proposal of a new combination of screening criteria for hepatitis C in France. Eur J Public Health 2009; 19: 52733.
  • 39
    Foucher J, Reiller B, Jullien V, et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. J Viral Hepat 2009; 16: 12131.
  • 40
    Delarocque-Astagneau E, Pillonel J, De Valk H, et al. An incident case–control study of modes of hepatitis C virus transmission in France. Ann Epidemiol 2007; 17: 75562.
  • 41
    Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G. A case–control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 2006; 13: 77582.
  • 42
    Courouce AM, Pillonel J, Saura C. Screening for markers of infections transmitted by transfusions in the blood collected in France from 1996 to 1998. Transfus Clin Biol 2000; 7: 15370.
  • 43
    Michault A, Faulques B, Sevadjan B, et al. Prevalence of hepatitis A, B, C virus markers in Reunion (south hospital and Saint Pierre prison). Bull Soc Pathol Exot 2000; 93: 3440.
  • 44
    Nalpas B, Zylberberg H, Dubois F, et al. Prevalence of infection by hepatitis viruses in a rural area. Analysis according to risk factors and alcohol consumption. Gastroenterol Clin Biol 2000; 24: 53640.
  • 45
    Ouzan D, Pesle B, Baldini E, et al. Epidemiological information obtained from anti-hepatitis C virus screening in blood donors and candidates for autologous transfusion from 1992 to 1996 in the Alpes-Maritimes region. Gastroenterol Clin Biol 2000; 24: 33741.
  • 46
    Pradat P, Trepo C. HCV: epidemiology, modes of transmission and prevention of spread. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 20110.
  • 47
    Frere T, Verneau A, Besson I, et al. Treatment of hepatitis C virus infection in the Poitou-Charentes region. Gastroenterol Clin Biol 1999; 23: 88791.
  • 48
    Merle V, Goria O, Gourier-Frery C, et al. Risk factors of contamination by hepatitis C virus. Case–control study in the general population. Gastroenterol Clin Biol 1999; 23: 43946.
  • 49
    Raguin G, Rosenthal E, Cacoub P, et al. Hepatitis C in France: a national survey in the Departments of Internal Medicine and Infectious Diseases. The GERMIVIC (Joint Study Group on Hepatitis C virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases). Eur J Epidemiol 1998; 14: 5458.
  • 50
    Bastie A, Pawlotsky JM, Roudot-Thoraval F, Dhumeaux D. Hepatitis C virus infection. Epidemiology. Pathol Biol 1995; 43: 67480.
  • 51
    Maisonneuve P, Aymard JP, Lemaire JM, Baillet A, Janot C. Serum antibodies to hepatitis C virus: analysis of risk factors of seropositivity in a population of blood donors in metropolitan France. Rev Med Interne 1991; 12: 4168.
  • 52
    Roudot-Thoraval F. Epidemiology of infections linked to hepatitis C virus in France. Bull Acad Natl Med 1996; 180: 125362.
  • 53
    Saura C, Pillonel J, Courouce AM. Screening for markers of blood-borne diseases in donated units collected in France from 1993 to 1995. Transfus Clin Biol 1997; 4: 40315.
  • 54
    French Institute for Public Health Surveillance (InVS). Institut de veille sanitaire. Hepatite C. Surveillance nationale de l'hepatite C a partir des poles de reference volontaires. Donnees 2001–2007.2010 Available at http://www.invs.sante.fr/surveillance/hepatite_c/poleref_volontaire/2001_2007/web-2007v2.pdf (accessed 28 September 2010).
  • 55
    Defossez G, Verneau A, Ingrand I, et al. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol 2008; 20: 36772.
  • 56
    Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999; 6: 43543.
  • 57
    Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 40513.
  • 58
    Pradat P, Caillat-Vallet E, Sahajian F, et al. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol 2001; 17: 4751.
  • 59
    Desenclos JC. Epidemiology of hepatitis C. Rev Prat 2000; 50: 106670.
  • 60
    Lefrere JJ. Descriptive epidemiology of hepatitis C virus infection in France in 1996. Transfus Clin Biol 1997; 4: 299319.
  • 61
    Jauffret-Roustide M, Le Strat Y, Couturier E, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis 2009; 9: 113.
  • 62
    Jauffret-Roustide M, Emmanuelli J, Desenclos JC. Limited impact of the harm-reduction policy on HCV among drug-users. The ANRS-Coquelicot survey example. Rev Epidemiol Sante Publique 2006; 54 (Spec No 1): 1S539.
  • 63
    Pillonel J, David D, Pinget R, Laperche S. Prevalence of HBV, HCV, HIV and HTLV in autologous blood donors in France between 1993 and 2000. Transfus Clin Biol 2002; 9: 28996.
  • 64
    Botte C, Janot C. Epidemiology of HCV infection in the general population and in blood transfusion. Nephrol Dial Transplant 1996; 11: 1921.
  • 65
    Aymard JP, Botte C, Contal P, Janot C, Streiff F. Seroprevalence of hepatitis C antibodies among blood donors. Study of second generation ELISA and RIBA tests and surrogate markers. Pathol Biol 1993; 41: 14953.
  • 66
    Aguelles O, Janot C. Epidemiology of anti-HCV antibodies in France. Viral Hepatitis Study Group of the French Blood Transfusion Society. Arch Virol Suppl 1992; 4: 24952.
  • 67
    Aymard JP, Janot C, Adjizian JC, et al. Serum antibodies against hepatitis C: study of 4,100 blood donors from the northeast of France. Rev Fr Transfus Hemobiol 1990; 33: 295302.
  • 68
    Ranger S, Martin P, Roussanne MC, Denis F. Prevalence of hepatitis C virus antibodies in the general population and in selected groups of patients in Limoges, France. Gut 1993; 34: S501.
  • 69
    Larsen C, Pialoux G, Salmon D, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill 2008; 13: 14.
  • 70
    Sahajian F, Vanhems P, Bailly F, et al. Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France. Eur J Public Health 2007; 17: 26371.
  • 71
    Ouzan D, Cavailler P, Hofliger P, et al. Modalities of care in anti HCV positive patients identified in General Medicine in the Alpes-Maritimes district. Gastroenterol Clin Biol 2003; 27: 37680.
  • 72
    Roudot-Thoraval F, Monnet E, Mercet P, et al. Strategies of hepatitis C screening in general practice. Results of a two-center randomized trial. Gastroenterol Clin Biol 2000; 24: 103741.
  • 73
    Djeriri K, Fontana L, Laurichesse H, et al. Seroprevalence of markers of viral hepatitis A, B and C in hospital personnel at the Clermont-Ferrand University Hospital Center. Presse Med 1996; 25: 14550.
  • 74
    Roudot-Thoraval F, Deforges L, Girollet PP, et al. Prevalence of hepatitis C virus antibodies (tests ELISA 2 and RIBA 2) in a population of pregnant women in France. Gastroenterol Clin Biol 1992; 16: 2559.
  • 75
    Bruandet A, Lucidarme D, Decoster A, et al. Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France. Rev Epidemiol Sante Publique 2006; 54 (Spec No 1): 1S1522.
  • 76
    Lucidarme D, Bruandet A, Ilef D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 2004; 132: 699708.
  • 77
    Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994; 46: 50411.
  • 78
    Cantaloube JF, Gallian P, Attoui H, et al. Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J Clin Microbiol 2005; 43: 36249.
  • 79
    Henquell C, Cartau C, Abergel A, et al. High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 2004; 42: 30305.
  • 80
    Tamalet C, Colson P, Tissot-Dupont H, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol 2003; 71: 3918.
  • 81
    Bourliere M, Barberin JM, Rotily M, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002; 9: 6270.
  • 82
    Elghouzzi MH, Bouchardeau F, Pillonel J, et al. Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. Vox Sang 2000; 79: 13844.
  • 83
    Stuyver L, Fretz C, Esquivel C, et al. Hepatitis C virus (HCV) genotype analysis in apparently healthy anti-HCV-positive Parisian blood donors. Transfusion 1996; 36: 5528.
  • 84
    Gournay J, Marcellin P, Martinot-Peignoux M, et al. Hepatitis C virus genotypes in French blood donors. J Med Virol 1995; 45: 399404.
  • 85
    Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171: 160710.
  • 86
    Sarrazin C, Berg T, Ross RS, et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289351.
  • 87
    Robert Koch Institute. Zur Situation wichtiger Infektionskrankheiten in Deutschland: virus hepatitis B, C und D im Jahr 2009. Epi Bull 2010; 20: 17790.
  • 88
    Huppe D, Zehnter E, Mauss S, et al. Epidemiology of chronic hepatitis C in Germany-an analysis of 10,326 patients in hepatitis centres and outpatient units. Z Gastroenterol 2008; 46: 3444.
  • 89
    Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000–2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005; 10: 811.
  • 90
    Deterding K, Wiegand J, Gruner N, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009; 47: 53140.
  • 91
    Gerner P, Wirth S, Wintermeyer P, Walz A, Jenke A. Prevalence of hepatitis C virus infection in children admitted to an urban hospital. J Infect 2006; 52: 3058.
  • 92
    Wiegand J, Kaiser T, Lobstein S, et al. Low prevalence of chronic hepatitis C, but high prevalence of elevated aminotransferases in a cohort of 2026 patients referred for orthopaedic surgery in the eastern part of Germany. Z Gastroenterol 2006; 44: 114.
  • 93
    Ammon A, Reichart PA, Pauli G, Petersen LR. Hepatitis B and C among Berlin dental personnel: incidence, risk factors, and effectiveness of barrier prevention measures. Epidemiol Infect 2000; 125: 40713.
  • 94
    Weber B, Rabenau H, Berger A, et al. Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany. Zentralbl Bakteriol 1995; 282: 10212.
  • 95
    Schlosser B, Domke D, Mockel M. High prevalence of chronic hepatitis C virus (HCV) infection in a German metropolitan area: a prospective screening analysis of 13,823 patients. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver, 22–26 April 2009, Copenhagen, Denmark, Poster (PDF), 2009.
  • 96
    Reimer J, Lorenzen J, Baetz B, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007; 22: 805.
  • 97
    Harder J, Walter E, Riecken B, et al. Hepatitis C virus infection in intravenous drug users Long-term follow-up after successful interferon therapy of acute hepatitis C. Clin Microbiol Infect 2004; 10: 76870.
  • 98
    Backmund M, Meyer K, Wachtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003; 18: 5638.
  • 99
    Stark K, Schreier E, Muller R, et al. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis 1995; 27: 3317.
  • 100
    Wiegand J, Luz B, Mengelkamp AK, et al. Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resources. J Viral Hepat 2009; 16: 7438.
  • 101
    Koerner K, Cardoso M, Dengler T, Kerowgan M, Kubanek B. Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang 1998; 74: 2136.
  • 102
    Seidl S, Kuhnl P, Beyer J, et al. Hepatitis C virus (HCV) antibodies in German blood donors – a pilot study. Beitr Infusionsther 1990; 26: 1821.
  • 103
    Zimmermann R, Konig V, Bauditz J, et al. Examination of a Berlin blood donation branch for antibodies to hepatitis C virus with the anti-HCV test and for circulating HCV-RNA using polymerase chain reaction. Beitr Infusionsther 1992; 30: 3841.
  • 104
    Palitzsch KD, Hottentrager B, Schlottmann K, et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol 1999; 11: 121520.
  • 105
    Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001; 17: 42935.
  • 106
    Lobstein S, Kaiser T, Liebert U, et al. Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients. Z Gastroenterol 2008; 46: 41520.
  • 107
    The Hepatitis C Trust. University of Southampton. The UK vs. Europe: Losing the fight against hepatitis C. London: The Hepatitis C Trust, 2006.
  • 108
    Schroter M, Zollner B, Schafer P, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002; 40: 18668.
  • 109
    Ross RS, Viazov SO, Holtzer CD, et al. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol 2000; 38: 35814.
  • 110
    Berg T, Hopf U, Stark K, et al. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatol 1997; 26: 48491.
  • 111
    Feucht HH, Schroter M, Zollner B, et al. The influence of age on the prevalence of hepatitis C virus subtypes 1a and 1b. J Infect Dis 1997; 175: 6858.
  • 112
    Feucht HH, Zollner B, Schroter M, et al. Distribution of genotypes and response to alpha-interferon in patients with hepatitis C virus infection in Germany. Eur J Clin Microbiol Infect Dis 1996; 15: 12832.
  • 113
    Savvas SP, Koskinas J, Sinani C, et al. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat 2005; 12: 5517.
  • 114
    Katsoulidou A, Sypsa V, Tassopoulos NC, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 1927.
  • 115
    Gatselis NK, Rigopoulou E, Stefos A, Kardasi M, Dalekos GN. Risk factors associated with HCV infection in semi-rural areas of central Greece. Eur J Intern Med 2007; 18: 4855.
  • 116
    Gogos CA, Fouka KP, Nikiforidis G, et al. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 2003; 18: 5517.
  • 117
    Raptopoulou M, Touloumi G, Tzourmakliotis D, et al. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia 2011; 15: 2631.
  • 118
    Goritsas C, Plerou I, Agaliotis S, et al. HCV infection in the general population of a Greek island: prevalence and risk factors. Hepatogastroenterology 2000; 47: 7825.
  • 119
    Panagopoulos P, Economou A, Kasimi A, et al. Prevalence of hepatitis B and C in the maternity department of a Greek district hospital. J Matern Fetal Neonatal Med 2004; 16: 10610.
  • 120
    Zervou EK, Boumba DS, Liaskos C, et al. Low prevalence of HCV, HIV, and HTLV-I/II infection markers in northwestern Greece: results of a 3-year prospective donor study (1995–1997). Eur J Intern Med 2003; 14: 3944.
  • 121
    Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur J Epidemiol 2001; 17: 7218.
  • 122
    Koulentaki M, Spanoudakis S, Kantidaki E, et al. Prevalence of hepatitis B and C markers in volunteer blood donors in Crete. A 5-year study. J Viral Hepat 1999; 6: 2438.
  • 123
    Mazokopakis E, Vlachonikolis J, Philalithis A, Lionis C. Seroprevalence of hepatitis A, B and C markers in Greek warship personnel. Eur J Epidemiol 2000; 16: 106972.
  • 124
    Hadziyannis SJ, Giannoulis G, Hadziyannis E, et al. Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma. J Hepatol 1993; 17 (Suppl. 3): S727.
  • 125
    Lionis C, Koulentaki M, Biziagos E, Kouroumalis E. Current prevalence of hepatitis A, B and C in a well-defined area in rural Crete, Greece. J Viral Hepat 1997; 4: 5561.
  • 126
    Koulentaki M, Ergazaki M, Moschandrea J, et al. Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study. BMC Public Health 2001; 1: 17.
  • 127
    Raptopoulou-Gigi M, Orphanou E, Lalla TH, Lita A, Garifallos A. Prevalence of hepatitis C virus infection in a cohort of pregnant women in northern Greece and transmission of HCV from mother to child. Eur J Epidemiol 2001; 17: 2636.
  • 128
    Lionis C, Vlachonikolis IG, Skliros S, et al. Do undefined sources of hepatitis C transmission exist? The Greek study in General Practice. J Viral Hepat 2000; 7: 21824.
  • 129
    Michos A, Terzidis A, Kalampoki V, et al. Seroprevalence and risk factors for hepatitis A, B, and C among Roma and non-Roma children in a deprived area of Athens, Greece. J Med Virol 2008; 80: 7917.
  • 130
    Lionis C, Frangoulis E, Koulentakis M, Biziagos E, Kouroumalis E. Prevalence of hepatitis A, B, and C markers in school children of a rural area of Crete, Greece. Eur J Epidemiol 1997; 13: 41720.
  • 131
    Sypsa V, Touloumi G, Tassopoulos NC, et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004; 11: 36674.
  • 132
    Sypsa V, Touloumi G, Papatheodoridis GV, et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005; 12: 54350.
  • 133
    Muller Z, Deak J, Horanyi M, et al. The detection of hepatitis C virus in South Hungary. J Clin Virol 2001; 20: 813.
  • 134
    Barna TK, Ozsvar Z, Szendrenyi V, Gal G. Hepatitis C virus antibody in the serum of blood donors. Orv Hetil 1996; 137: 50711.
  • 135
    Merkinaite S. HCV infection in Europe. Siauliu St. 5/1-21, Vilnius 01133, Lithuania: Eurasian Harm Reduction Network (EHRN), formerly Central and Eastern European Harm Reduction Network (CEEHRN), 1 October 2007.
  • 136
    European Monitoring Centre for Drugs and Drug Addiction. EMCDDA 2010 Selected Issue-Trends in Injecting Drug use in Europe European Union. Annual Report. Selected Issues/European Monitoring Centre for Drugs and Drug Addicton. European Monitoring Centre for Drugs and Drug Addiction, 2010, 22pp.
  • 137
    Mihaly I, Telegdy L, Ibranyi E, et al. Prevalence, genotype distribution and outcome of hepatitis C infections among the employees of the Hungarian Central Hospital for infectious diseases. J Hosp Infect 2001; 49: 23944.
  • 138
    McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 88492.
  • 139
    Gervain J, Simon G Jr, Papp I, Szabone BK. Determination of the type and subtype of the hepatitis C virus in chronic viral hepatitis patients in Hungary. Orv Hetil 2001; 142: 13159.
  • 140
    Sarvari C, Ujhelyi E, Szlávik J, et al Determination of hepatitis C virus genotypes in Hungary using the Trugene HCV 5'NC genotyping test. ISMD2010 Eighth International Symposium on Molecular Diagnostics 2010 Graz, Austria De Gruyter 2010, A21.
  • 141
    Muller Z, Deak J, Ross RS, et al. Hepatitis C virus genotypes in Hungarian and Austrian patients with chronic hepatitis C. J Clin Virol 2003; 26: 295300.
  • 142
    Zuckerman E. Liver Unit, Carmel Medical Center, Haifa, Israel. Hepatitis C in Israel. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 2 October 2010.
  • 143
    Kerzman H, Green MS, Shinar E. Risk factors for hepatitis C virus infection among blood donors in Israel: a case–control study between native Israelis and immigrants from the former Soviet Union. Transfusion 2007; 47: 118996.
  • 144
    Glikberg F, Brawer-Ostrovsky J, Ackerman Z. Very high prevalence of hepatitis B and C in Bukharian Jewish immigrants to Israel. J Clin Gastroenterol 1997; 24: 303.
  • 145
    Lurie Y, Landau DA, Blendis L, et al. Acute hepatitis C in Israel: a predominantly iatrogenic disease? J Gastroenterol Hepatol 2007; 22: 15864.
  • 146
    Almog R, Low M, Cohen D, et al. Prevalence of anti-hepatitis A antibodies, hepatitis B viral markers, and anti-hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990–1991. Infection 1999; 27: 2127.
  • 147
    Flatau E, Segol O, Shneour A, Tabenkin H, Raz R. Prevalence of markers of infection with hepatitis B and C viruses in immigrants of operation Solomon, 1991. Isr J Med Sci 1993; 29: 3879.
  • 148
    Stern M, Manny N, Klein A, et al. A study of Israeli blood donors, asymptomatic carriers of hepatitis C virus, in relation to liver disease, cryoglobulinemia and transmission. Isr J Med Sci 1995; 31: 2779.
  • 149
    Bar-Shany S, Green MS, Slepon R, Shinar E. Ethnic differences in the prevalence of anti-hepatitis C antibodies and hepatitis B surface antigen in Israeli blood donors by age, sex, country of birth and origin. J Viral Hepat 1995; 2: 13944.
  • 150
    Shemer-Avni Y, el Astral Z, Kemper O, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. J Med Virol 1998; 56: 2303.
  • 151
    Zuckerman E. Liver Unit, Carmel Medical Center, Haifa, Israel. Sources for the epidemiology of hepatitis C in Israel. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 2 August 2010.
  • 152
    Loebstein R, Mahagna R, Maor Y, et al. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors. Isr Med Assoc J 2008; 10: 7758.
  • 153
    Maor Y, Bashari D, Kenet G, et al. Hepatitis C at the Israeli National Hemophilia Center. Haemophilia 2006; 12: 6874.
  • 154
    Sermoneta-Gertel S, Donchin M, Adler R, et al. Hepatitis c virus infection in employees of a large university hospital in Israel. Infect Control Hosp Epidemiol 2001; 22: 75461.
  • 155
    Bogomolski-Yahalom V, Ashur Y, Klein A, Tur-Kaspa R. Hepatitis C virus genotypes in patients with persistent infection – a preliminary report. Isr J Med Sci 1997; 33: 1822.
  • 156
    Ministry of Health Israel, Department of Epidemiology. Infectious Diseases: Morbidity in Israel. Israel Morbidity Report. Ministry of Health Israel, Department of Epidemiology, 2010, 129pp.
  • 157
    Cozzolongo R, Osella AR, Elba S, et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol 2009; 104: 27406.
  • 158
    Fusco M, Girardi E, Piselli P, et al. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer 2008; 44: 84753.
  • 159
    Di Stefano R, Stroffolini T, Ferraro D, et al. Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J Med Virol 2002; 67: 33944.
  • 160
    La Torre G, De Vito E, Langiano E, et al. Epidemiology of hepatitis C virus antibodies in blood donors from the province of Latina, Italy. Eur J Epidemiol 2003; 18: 6914.
  • 161
    Fabris P, Baldo V, Baldovin T, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 2008; 42: 52732.
  • 162
    Beggio M, Giraldo M, Borella-Venturini M, et al. Prevalence of hepatitis virus A, B, and C markers according to the geographic origin of medical students. G Ital Med Lav Ergon 2007; 29: 7457.
  • 163
    Petti S, Divizia M, Donia D, et al. Analysis of the shift of the transmission pattern for hepatitis C in a community in Central Italy. New Microbiol 2006; 29: 2079.
  • 164
    Raja M, Azzoni A, Pucci D. Characteristics of HCV positive patients in an Italian urban psychiatric unit. Clin Pract Epidemol Ment Health 2006; 2: 26.
  • 165
    Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 32732.
  • 166
    Montella M, Crispo A, Grimaldi M, et al. Prevalence of hepatitis C virus infection in different population groups in southern Italy. Infection 2005; 33: 912.
  • 167
    Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005; 41: 11519.
  • 168
    Montella M, Crispo A, Serraino D, Rezza G, Franceschi S. Is the spread of HCV in Southern Italy attributable to iatrogenic transmission through unsterile injections? Eur J Cancer Prev 2003; 12: 856.
  • 169
    Cecere A, Marotta F, Lucariello A, et al. High prevalence of hepatitis C virus infection in a southern Italian rural region. Clinical aspects and evidence of inapparent parenteral exposure. Panminerva Med 2003; 45: 2539.
  • 170
    Catalani C, Biggeri A, Gottard A, et al. Prevalence of HCV infection among health care workers in a hospital in central Italy. Eur J Epidemiol 2004; 19: 737.
  • 171
    Proietti L, Origlio A, Sandona PB, Duscio D, Malaguarnera M. Prevalence of HCV in health care workers in Southern Italy. Clin Ter 2003; 154: 15962.
  • 172
    Mazzeo C, Azzaroli F, Giovanelli S, et al. Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut 2003; 52: 10304.
  • 173
    Bongiorno MR, Pistone G, Arico G. Hepatitis B and hepatitis C virus infections in dermatological patients in west Sicily: a seroepidemiological study. J Eur Acad Dermatol Venereol 2002; 16: 436.
  • 174
    Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002; 50: 6936.
  • 175
    Campello C, Poli A, Dal Molin G, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection 2002; 30: 712.
  • 176
    Raffaele A, Valenti M, Iovenitti M, et al. High prevalence of HCV infection among the general population in a rural area of central Italy. Eur J Epidemiol 2001; 17: 416.
  • 177
    Baldo V, Floreani A, Menegon T, Angiolelli G, Trivello R. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. The Collaborative Group. Gerontology 2001; 46: 1948.
  • 178
    Baldo V, Floreani A, Menegon T, et al. Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: a seroepidemiological study. Eur J Epidemiol 2000; 16: 8791.
  • 179
    Coppola RC, Masia G, Pradat P, et al. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat 2000; 7: 1307.
  • 180
    Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31: 7515.
  • 181
    Maio G, D'Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol 2000; 33: 11620.
  • 182
    Maggi G, Armitano S, Brambilla L, et al. Hepatitis C infection in an Italian population not selected for risk factors. Liver 1999; 19: 42731.
  • 183
    Osella AR, Sonzogni L, Cavallini A, et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. J Clin Microbiol 1999; 37: 23712.
  • 184
    Natali A, Dieci E, Pilotti E, Chezzi C. Prevalence of hepatitis C virus antibodies in a clinic-based group of Italians from one geographic area. Clin Microbiol Infect 1999; 5: 1259.
  • 185
    Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 87480.
  • 186
    Comandini UV, Tossini G, Longo MA, et al. Sporadic hepatitis C virus infection: a case–control study of transmission routes in a selected hospital sample of the general population in Italy. Scand J Infect Dis 1998; 30: 115.
  • 187
    Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26: 100611.
  • 188
    Tanzi M, Bellelli E, Benaglia G, et al. The prevalence of HCV infection in a cohort of pregnant women, the related risk factors and the possibility of vertical transmission. Eur J Epidemiol 1997; 13: 51721.
  • 189
    Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol 1997; 27: 305.
  • 190
    Floreani A, Paternoster D, Zappala F, et al. Hepatitis C virus infection in pregnancy. Br J Obstet Gynaecol 1996; 103: 3259.
  • 191
    Puro V, Petrosillo N, Ippolito G, et al. Occupational hepatitis C virus infection in Italian health care workers. Italian Study Group on Occupational Risk of Bloodborne Infections. Am J Public Health 1995; 85: 12725.
  • 192
    Stroffolini T, Menchinelli M, Taliani G, et al. High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure. Ital J Gastroenterol 1995; 27: 2358.
  • 193
    D'Amelio R, Stroffolini T, Matricardi PM, et al. Low prevalence of anti-HCV antibodies among Italian Air Force recruits. Scand J Infect Dis 1995; 27: 124.
  • 194
    Romano L, Azara A, Chiaramonte M, et al. Low prevalence of anti-HCV antibody among Italian children. Infection 1994; 22: 3502.
  • 195
    Marranconi F, Fabris P, Stecca C, et al. Prevalence of anti-HCV and risk factors for hepatitis C virus infection in healthy pregnant women. Infection 1994; 22: 3337.
  • 196
    Puro V, Lo PE, D'Ascanio I, et al. The seroprevalence of HIV, HBV and HCV infections in patients coming to the departments of general surgery of a public hospital (S. Camillo, Rome). Minerva Chir 1993; 48: 34954.
  • 197
    Gessoni G, Manoni F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. Eur J Med 1993; 2: 7982.
  • 198
    Campello C, Majori S, Poli A, et al. Prevalence of HCV antibodies in health-care workers from northern Italy. Infection 1992; 20: 2246.
  • 199
    Rapicetta M, Attili AF, Mele A, et al. Prevalence of hepatitis C virus antibodies and hepatitis C virus-RNA in an urban population. J Med Virol 1992; 37: 8792.
  • 200
    Albano A, Pianetti A, Biffi MR, et al. Prevalence of anti-HCV in subjects of various age groups. Eur J Epidemiol 1992; 8: 30911.
  • 201
    Mariano A, Scalia TG, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009; 41: 68999.
  • 202
    Tosti ME, Solinas S, Prati D, et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol 2002; 117: 2159.
  • 203
    Sereno S, Perinelli P, Laghi V. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 2009; 45: 3547.
  • 204
    Pizzillo P, Almasio PL, Ferraro D, Craxi A, Di Stefano R. HCV genotypes in Sicily: is there any evidence of a shift? J Med Virol 2009; 81: 10406.
  • 205
    Cenci M, Massi M, Alderisio M, De Soccio G, Recchia O. Prevalence of hepatitis C virus (HCV) genotypes and increase of type 4 in central Italy: an update and report of a new method of HCV genotyping. Anticancer Res 2007; 27: 121922.
  • 206
    Cenci M, De Soccio G, Recchia O. Prevalence of hepatitis C virus (HCV) genotypes in central Italy. Anticancer Res 2003; 23: 512932.
  • 207
    Dal Molin G, Ansaldi F, Biagi C, et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 2002; 68: 3526.
  • 208
    Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis 2002; 42: 16973.
  • 209
    Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003; 38: 86470.
  • 210
    Melum E, Schrumpf E, Bjoro K. Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation. Scand J Gastroenterol 2006; 41: 5926.
  • 211
    Vik IS, Skaug K, Dalgard O, Steen TW, Hoddevik G. Hepatitis C – a health problem also in Norway. Tidsskr Nor Laegeforen 2008; 128: 5636.
  • 212
    Kristiansen MG, Gutteberg T, Berg LK, et al. Hepatitis C in Northern Norway – an 8-year material. Tidsskr Nor Laegeforen 2002; 122: 19746.
  • 213
    Eskild A, Samdal HH, Skaug K, et al. Hepatitis C virus among pregnant women in Norway – occurrence of antibodies and pregnancy outcome. Tidsskr Nor Laegeforen 2000; 120: 10068.
  • 214
    Nordoy I, Schrumpf E, Elgjo K, et al. Liver disease in anti-hepatitis C virus-positive Norwegian blood donors. Scand J Gastroenterol 1994; 29: 7781.
  • 215
    Dalgard O, Mangia A. Management of patients with hepatitis C virus genotype 2 or 3: comments on updated American Association for the Study of Liver Diseases practice guidelines. Hepatology 2009; 50: 3235.
  • 216
    Dalgard O, Egeland A, Ervik R, et al. Risk factors for hepatitis C among injecting drug users in Oslo. Tidsskr Nor Laegeforen 2009; 129: 1014.
  • 217
    Kielland KB, Siebke JC. Hepatitis A-, B- and C-markers among Norwegian drug addicts in the period 1975–89. Tidsskr Nor Laegeforen 1991; 111: 8214.
  • 218
    Dalgard O. Medical Department, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Estimated incidence of hepatitis C in Norway. Conversation with Wallace C. Center for Disease Analysis, Kromite, Louisville, CO, USA, 18 February 2011.
  • 219
    Bell H, Hellum K, Harthug S, et al. Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group. Scand J Infect Dis 1996; 28: 3579.
  • 220
    Warunek W, Librant-Suska M, Krukowiecki J, et al. Epidemiologic and clinical characteristics of patients with hepatitis type C on the bases of selected parameters. Folia Med Cracov 1996; 37: 719.
  • 221
    Chlabicz S, Flisiak R, Grzeszczuk A, et al. Known and probable risk factors for hepatitis C infection: a case series in north-eastern Poland. World J Gastroenterol 2006; 12: 1415.
  • 222
    Chlabicz S, Grzeszczuk A, Prokopowicz D. Medical procedures and the risk of iatrogenic hepatitis C infection: case–controlled study in north-eastern Poland. J Hosp Infect 2004; 58: 2049.
  • 223
    Labedzka H, Simon K, Gladysz A. Clinical and epidemiological assessment of hepatitis C virus infection among voluntary blood donors. Med Sci Monit 2002; 8: CR5916.
  • 224
    Flisiak R, Halota W, Horban A, et al. Prevalence of anti-HCV and HCV-RNA among health care workers and patients of multispecialistic hospitals in Poland. J Hepatol. 2011; 54(Suppl. 1): S456.
  • 225
    Bielawski K, Wlasiuk M, Truskolawska M, Falkiewicz B. HCV infection in Poland. Arch Med Res 2000; 31: 5325.
  • 226
    Borzecka B, Bludzin W. The program of early detection of HCV infection. Przegl Epidemiol 2007; 61: 7338.
  • 227
    Braczkowska B, Kowalskan M, Zejda JE, et al. Prevalence and basic determinants of hepatitis C antibodies in medical students in Katowice, Poland. Przegl Lek 2006; 63: 53942.
  • 228
    Swincow G, Nowak A, Czarnecki R, Czerwionka-Szaflarska M. Prevalence of HCV infection in infants – own clinical experience. Med Wieku Rozwoj 2006; 10: 40715.
  • 229
    Seyfried H, Brojer E, Grabarczyk P, et al. Prevalence of hepatitis C virus markers in Polish blood donors in 1994–2003. Przegl Epidemiol 2005; 59: 80714.
  • 230
    Chlabicz S, Bonifatiuk I, Radziwon P. Prevalence of hepatitis C virus antibodies among blood donors in north-eastern Poland. Hepatol Res 2005; 33: 20610.
  • 231
    Stepien M, Rosinska M. Hepatitis C in Poland in 2008. Przegl Epidemiol 2010; 64: 24550.
  • 232
    Rosinska M, Czarkowski MP. Hepatitis C in Poland in 2005. Przegl Epidemiol 2007; 61: 2816.
  • 233
    Czarkowski MP. Hepatitis C in Poland in 2004. Przegl Epidemiol 2006; 60: 4816.
  • 234
    Czarkowski MP, Kuszewski K. Hepatitis C in Poland in 2003. Przegl Epidemiol 2005; 59: 3038.
  • 235
    Kuszewski K, Czarkowski MP. Hepatitis C in Poland in 2002. Przegl Epidemiol 2004; 58: 1317.
  • 236
    Bielak A. Hepatitis C in Poland in 2001. Przegl Epidemiol 2003; 57: 1258.
  • 237
    Bobel D, Rosinska M. Hepatitis C in Poland in 2006. Przegl Epidemiol 2008; 62: 32532.
  • 238
    Mazurek J. Hepatitis C in Poland in 2000. Przegl Epidemiol 2002; 56: 3258.
  • 239
    Laskus I, Rosinska M. Hepatitis C in Poland in 2007. Przegl Epidemiol 2009; 63: 2514.
  • 240
    Chlabicz S, Flisiak R, Kowalczuk O, et al. Changing HCV genotypes distribution in Poland – relation to source and time of infection. J Clin Virol 2008; 42: 1569.
  • 241
    Brojer E, Gronowska A, Medynska J, et al. The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA-positive, hepatitis C virus antibody-negative blood donors identified in the nucleic acid test screening program in Poland. Transfusion 2004; 44: 170610.
  • 242
    Areias J, Gomes H, Mocho ML, et al. Epidemiological characterization of chronic hepatitis C in Portugal. Gastroenterología y hepatología 2006; 29: 1478.
  • 243
    Santos A, Carvalho A, Bento D, et al. Epidemiology of hepatitis C in central Portugal. Prevalence of anti-HCV in the population of the Coimbra District. Acta Med Port 1994; 7: S38.
  • 244
    Marinho RT, Moura MC, Giria JA, Ferrinho P. Epidemiological aspects of hepatitis C in Portugal. J Gastroenterol Hepatol 2001; 16: 10767.
  • 245
    Ramalho F, Costa A, Pires A, et al. Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci 2000; 45: 1827.
  • 246
    De Carvalho A, Martinho A, Leitao J, et al. HCV genotypes. Liver histopathology and immunologic profile in four groups of patients. Acta Med Port 2000; 13: 6775.
  • 247
    Goldis A. Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Comments on the Romania portion of HCV manuscript. Conversation with Largen A. Center for Disease Analysis, Kromite, Louisville, CO, USA, 15 November 2010.
  • 248
    Grigorescu M. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis 2009; 18: 4550.
  • 249
    Gheorghe L, Grigorescu M, Iacob S, et al. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice. Rom J Gastroenterol 2005; 14: 10915.
  • 250
    Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16: 239.
  • 251
    Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania: different from European rates? J Hepatol 2008; 49: 6612.
  • 252
    Azoicai D, Ivan A, Carasievici E, et al. The prevalence of the owner of serologic markers for the hepatitis C virus, in a north-eastern territory of Romania. Rev Med Chir Soc Med Nat Iasi 2001; 105: 12731.
  • 253
    Ivan A, Azoicai D, Filimon R, et al. The epidemiological aspects and prevalence of markers in those with viral hepatitis C in some population categories in 1994–1997 in Iasi County. Bacteriol Virusol Parazitol Epidemiol 1998; 43: 2759.
  • 254
    Ivan A, Azoicai D, Grigorescu R, et al. Seroepidemiological considerations of the incidence of viral hepatitis C in some population groups. Rev Med Chir Soc Med Nat Iasi 1995; 99: 12938.
  • 255
    Molnar GB, Popa S, Jebeleanu L, Damian C. A prevalence study of serum markers in hepatitis virus infection in the epidemiological anamnesis of the population. Bacteriol Virusol Parazitol Epidemiol 1994; 39: 14150.
  • 256
    Paquet C, Babes VT, Drucker J, Senemaud B, Dobrescu A. Viral hepatitis in Bucharest. Bull World Health Organ 1993; 71: 7816.
  • 257
    Russian Federation MoH. Viral hepatitis prophylaxis, general rules of epidemiology surveillance for viral hepatitis. Russian Federation Ministry of Health, 2000.
  • 258
    Mikhailov MI, Gomberg MA, Dolzhanskaya NA, Koubanova AA. Significance of sexual route of transmission of hepatitis B and C in Russia. Int J STD AIDS 2002; 13 (Suppl. 2): 911.
  • 259
    Abdourakhmanov DT, Hasaev AS, Castro FJ, Guardia J. Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan. Eur J Epidemiol 1998; 14: 54953.
  • 260
    Gaidarenko AD. Prediction of Epidemic of Hepatitis C through Computer Simulation. Moscow: Scientific Research Institute of epidemiology and microbiology. N.F. Gamalei Russian Academy of medical sciences, 2009.
  • 261
    Zhiburt EB, Asadi AK, Cherkasov EG, Reizman PV. The verification of the results of screening antibodies to hepatitis C virus in blood donors. Zh Mikrobiol Epidemiol Immunobiol 2005; 5: 713.
  • 262
    Reshetnikov OV, Khryanin AA, Teinina TR, Krivenchuk NA, Zimina IY. Hepatitis B and C seroprevalence in Novosibirsk, western Siberia. Sex Transm Infect 2001; 77: 463.
  • 263
    Kuzin SN, Lisitsina EV, Samokhvalov EI, et al. Spread of hepatitis C and separate genotypes of hepatitis C virus in a region with a moderately active epidemic process. Vopr Virusol 1999; 44: 7982.
  • 264
    Ariamkina OL, Grigor'ev I, Fadeeva GE, et al. The diagnosis of hepatitis C viral infection in blood donors and patients. Zh Mikrobiol Epidemiol Immunobiol 1998; 1: 747.
  • 265
    Lytsar BN, Skvortsov SV, Poliakova II, Lobanova VI, Belov EV. Detection of antibodies to hepatitis C virus in blood donors. Gematol Transfuziol 1993; 38: 2931.
  • 266
    Sychev A, Mikhailov MI. The hepatitis C virus infection of Moscow blood donors. Zh Mikrobiol Epidemiol Immunobiol 1993; 4: 803.
  • 267
    Zhiburt EB, Danil'chenko VV, Bel'gesov NV, et al. Specific and substitute markers of hepatitis C in screening donor blood. Gematol Transfuziol 1995; 40: 168.
  • 268
    Abe K, Hayakawa E, Sminov AV, et al. Molecular epidemiology of hepatitis B, C, D and E viruses among children in Moscow, Russia. J Clin Virol 2004; 30: 5761.
  • 269
    Ohba K, Mizokami M, Kato T, et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. Epidemiol Infect 1999; 122: 13943.
  • 270
    Iashina TL, Favorov MO, Shakhgil'dian IV, et al. The spread of hepatitis C markers among the population of regions of Russia and Central Asia. Zh Mikrobiol Epidemiol Immunobiol 1993; 5: 469.
  • 271
    Lvov DK, Samokhvalov EI, Tsuda F, et al. Prevalence of hepatitis C virus and distribution of its genotypes in Northern Eurasia. Arch Virol 1996; 141: 161322.
  • 272
    Onishchenko GG, Shakhgil'dian IV. The current problems in the epidemiology and prevention of viral hepatitis B and C in the Russian Federation. Zh Mikrobiol Epidemiol Immunobiol 2000; 1: 504.
  • 273
    Sagalova O. Chelyabinsk State Medical Academy, Chelyabinsk, Russian Federation. Hepatitis C in Russia from the Ministry of Health and Social Development. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 15 July 2010.
  • 274
    Asratian AA, Isaeva OV, Mikhailov MI. Tendency and analysis of the epidemic situation in parenteral virus hepatitis B and C in the Russian Federation and a number of its regions. Zh Mikrobiol Epidemiol Immunobiol 2005; 4: 405.
  • 275
    Shustov AV, Kochneva GV, Sivolobova GF, et al. Molecular epidemiology of the hepatitis C virus in Western Siberia. J Med Virol 2005; 77: 3829.
  • 276
    Maksyutov RA, Gavrilova EV, Kanev AN. The distribution of genotypes of hepatitis C in the Russian regions. Annual All-Russian Congress on Infectious Diseases, Moscow, 29–31 March 2010, Moscow, 186.
  • 277
    Ariamkina OL. HCV infection in Ulyanovsk region. Epidemiologiia i infektsionnye bolezni. Epidemiol Infect Dis 2005; 4: 149.
  • 278
    Kovalev SI, Maliushenko OI, Glinskikh NP. Genetic variations of hepatitis C virus circulating in the Ural region. Vopr Virusol 2003; 48: 114.
  • 279
    L'vov DK, Mishiro S, Selivanov NA, et al. Prevalence of genotypes of the hepatitis C virus, circulating in northwestern and central parts of Russia. Vopr Virusol 1995; 40: 2513.
  • 280
    Echevarria JM, Leon P, Pozo F, Avellon A. Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996–2004). Enferm Infecc Microbiol Clin 2006; 24: 205.
  • 281
    Martinez-Bauer E, Forns X, Armelles M, et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008; 48: 207.
  • 282
    Bruguera M, Forns X, Trapero-Marugan M, et al. Hepatitis C in Spain. Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Med Clin 2006; 127: 1137.
  • 283
    Martinez SM, Delgado MB, Castroagudin JF, Aguilera A. High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain. J Clin Microbiol 2005; 43: 54034.
  • 284
    Sola R, Cruz De Castro E, Hombrados M, et al. Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study. Med Clin 2002; 119: 905.
  • 285
    Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001; 65: 68893.
  • 286
    Forns X, Martinez-Bauer E, Feliu A, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005; 41: 11522.
  • 287
    Riestra S, Fernandez E, Leiva P, et al. Prevalence of hepatitis C virus infection in the general population of northern Spain. Eur J Gastroenterol Hepatol 2001; 13: 47781.
  • 288
    Chimeno MM, Chocarro A, Brezmes P, Ochoa C, Perez J. Seroprevalence of hepatitis C virus in the general population. Enferm Infecc Microbiol Clin 2002; 20: 647.
  • 289
    Suarez Gonzalez A, Solis Sanchez G, Otero Guerra L, et al. Prevalence of immunity to hepatitis viruses in pregnant women from the health area of Gijon (Spain). Gastroenterol Hepatol 2004; 27: 34752.
  • 290
    Gutierrez-Zufiaurre N, Sanchez-Hernandez J, Munoz S, et al. Seroprevalence of antibodies against Treponema pallidum, Toxoplasma gondii, rubella virus, hepatitis B and C virus, and HIV in pregnant women]. Enferm Infecc Microbiol Clin 2004; 22: 5126.
  • 291
    Munoz-Almagro C, Juncosa T, Fortuny C, et al. Prevalence of hepatitis C virus in pregnant women and vertical transmission. Med Clin 2002; 118: 4524.
  • 292
    Prieto Domingo JJ, Carrion Bolanos JA, Bandres MF. Prevalence of hepatitis C virus and excessive consumption of alcohol in a nonhospital worker population. Gastroenterol Hepatol 1997; 20: 47983.
  • 293
    Suarez A, Viejo G, Navascues CA, et al. The prevalence of hepatitis A, B and C viral markers in the population of Gijon between 26 and 65 years old. Gastroenterol Hepatol 1997; 20: 34752.
  • 294
    Ferrer F, Candela MJ, Garcia C, et al. A comparative study of two third-generation anti-hepatitis C virus ELISAs. Haematologica 1997; 82: 6901.
  • 295
    Munoz-Gomez R, Garcia-Monzon C, Garcia-Buey L, et al. Hepatitis C virus infection in Spanish volunteer blood donors: HCV RNA analysis and liver disease. Eur J Gastroenterol Hepatol 1996; 8: 2737.
  • 296
    Garcia-Bengoechea M, Emparanza JI, Sarriugarte A, et al. Antibodies to hepatitis C virus: a cross-sectional study in patients attending a trauma unit or admitted to hospital for elective surgery. Eur J Gastroenterol Hepatol 1995; 7: 23741.
  • 297
    Suarez A, Rodriguez M, Riestra S, et al. The prevalence of anti-HCV positivity among blood donors in Asturias. A clinical–epidemiologic study. Med Clin 1994; 103: 60610.
  • 298
    Esteban JI, Lopez-Talavera JC, Genesca J, et al. Evaluation of anti-HCV positive blood donors identified during routine screening. Arch Virol Suppl 1992; 4: 2446.
  • 299
    Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 4439.
  • 300
    Martinez JL, del Hierro J, Camarero A, et al. Hepatitis C virus infection in different risk groups and among blood donors. Enferm Infecc Microbiol Clin 1991; 9: 34550.
  • 301
    Martin Y, Marzo L, Cinto F, Delgado P, Bunuel C. Incidence of anti-HCV and ALT in blood donors. Sangre 1990; 35: 197200.
  • 302
    Salmeron J, Gimenez F, Torres C, et al. Epidemiology and prevalence of seropositivity for hepatitis C virus in pregnant women in Granada. Rev Esp Enferm Dig 1998; 90: 84150.
  • 303
    Sacristan B, Gastanares MI, Elena A, et al. Seroepidemiologic study of hepatitis C virus infection in a general population from the region of La Rioja, Spain. Med Clin 1996; 107: 3315.
  • 304
    Gil Miguel A, Ruedas A, Santos Santos M, Rey Calero YJ. Prevalence of hepatitis C virus infection in school children in an urban and suburban area of Madrid. Aten Primaria 1996; 17: 5212.
  • 305
    Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, et al. Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis 1996; 28: 1720.
  • 306
    Salleras L, Bruguera M, Vidal J, et al. Seroepidemiology of hepatitis C virus infection in pregnant women in Catalonia. Med Clin 1994; 103: 7214.
  • 307
    Jaqueti J, Navarro-Gallar F, Martinez-Hernandez D, et al. Prevalence of antibodies against the hepatitis C virus among the staff of a general hospital. Rev Esp Enferm Dig 1991; 80: 334.
  • 308
    Muga R, Sanvisens A, Bolao F, et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987–2001. Drug Alcohol Depend 2006; 82 (Suppl. 1): S2933.
  • 309
    Lumbreras B, Jarrin I, del Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006; 20: 1116.
  • 310
    Jimenez Fabrega X, Carballo AA, Batalla MC, et al. The prevalence of infection by the hepatitis B, C and human immunodeficiency viruses in drug users. Aten Primaria 1999; 24: 36871.
  • 311
    Santana Rodriguez OE, Male Gil ML, HernandezSantana JF, Liminana Canal JM, Martin Sanchez AM. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol 1998; 14: 55561.
  • 312
    Bolumar F, Hernandez-Aguado I, Ferrer L, et al. Prevalence of antibiotics to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990–1992. Int J Epidemiol 1996; 25: 2049.
  • 313
    Payeras Cifre A, Socias Moya M, Forteza-Rei Borralleras J, Besalduch Vidal J. Hepatitis C viral infection and the consumption of intravenous drugs. Rev Sanid Hig Publica 1992; 66: 2337.
  • 314
    Ramos B, Nunez M, Toro C, et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 2007; 54: 1739.
  • 315
    Fernandez-Arcas N, Lopez-Siles J, Trapero S, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol 2006; 78: 142935.
  • 316
    Moreno Planas JM, Fernandez Ruiz M, Portero Azorin F, et al. Prevalence of hepatitis C virus genotypes in a Spanish liver transplant unit. Transplant Proc 2005; 37: 14867.
  • 317
    Rodriguez JC, Garcia J, Moya I, et al. Genetic variability of hepatitis C virus in the health area of Elche (Spain). Correlation between core antigen and viral load. Gastroenterol Hepatol 2003; 26: 40710.
  • 318
    Duberg A, Janzon R, Back E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill 2008; 13: 15.
  • 319
    Duberg AS, Pettersson H, Aleman S, et al. The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepat 2011; 18: 10618.
  • 320
    Shev S, Widell A, Foberg U, et al. HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile. Infection 1995; 23: 2537.
  • 321
    Lidman C, Norden L, Kaberg M, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009; 41: 67984.
  • 322
    Hoffmann G, Berglund G, Elmstahl S, et al. Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population. Scand J Gastroenterol 2000; 35: 8615.
  • 323
    Struve J, Norrbohm O, Stenbeck J, Giesecke J, Weiland O. Risk factors for hepatitis A, B and C virus infection among Swedish expatriates. J Infect 1995; 31: 2059.
  • 324
    Lindholm A. Epidemiology of viral infections in the Swedish blood-donor population. Blood Coagul Fibrinolysis 1994; 5: S137.
  • 325
    European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2008. Report on the State of Communicable Diseases in the EU and EEA/EFTA Countries. European Centre for Disease Prevention and Control, 2008.
  • 326
    Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol 2005; 34: 10814.
  • 327
    Widell A, Verbaan H, Wejstal R, et al. Hepatocellular carcinoma in Sweden: its association with viral hepatitis, especially with hepatitis C viral genotypes. Scand J Infect Dis 2000; 32: 14752.
  • 328
    Westin J, Lindh M, Lagging LM, Norkrans G, Wejstal R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999; 31: 3558.
  • 329
    Widell A, Shev S, Mansson S, et al. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications. J Med Virol 1994; 44: 2729.
  • 330
    Prasad L, Spicher VM, Zwahlen M, et al. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007; 36: 7317.
  • 331
    Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat 2009; 16: 6449.
  • 332
    Federal Office of Public Health (FOPH). Health in Switzerland, Switzerland, 27 August 2010.
  • 333
    Gerlich M, Gschwend P, Uchtenhagen A, Kramer A, Rehm J. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol 2006; 21: 5459.
  • 334
    Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001; 11: 42530.
  • 335
    Ladewig D. A reduction in HIV positive and an increase in hepatitis C positive subjects in methadone maintenance treatments. Swiss Med Wkly 2001; 131: 422.
  • 336
    Broers B, Junet C, Bourquin M, et al. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998; 12: 205966.
  • 337
    Diamantis I, Bassetti S, Erb P, et al. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997; 26: 7947.
  • 338
    Russmann S, Dowlatshahi EA, Printzen G, et al. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol 2007; 7: 5.
  • 339
    Ambuhl PM, Binswanger U, Renner EL. Epidemiology of chronic hepatitis B and C among dialysis patients in Switzerland. Schweiz Med Wochenschr 2000; 130: 3418.
  • 340
    Candinas D, Joller-Jemelka HI, Schlumpf R, et al. Hepatitis C RNA prevalence in a Western European organ donor pool and virus transmission by organ transplantation. J Med Microbiol 1994; 41: 2203.
  • 341
    Zucca E, Roggero E, Maggi-Solca N, et al. Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica 2000; 85: 14753.
  • 342
    Weber C, Collet S, Fried R, et al. Low prevalence of hepatitis C virus antibody among Swiss dental health care workers. J Hepatol 2001; 34: 9634.
  • 343
    Lavanchy D, Mayerat C, Morel B, et al. Evaluation of third-generation assays for detection of anti-hepatitis C virus (HCV) antibodies and comparison with presence of HCV RNA in blood donors reactive to c100-3 antigen. J Clin Microbiol 1994; 32: 22725.
  • 344
    Prasad LR, Massery Spicher V, Kammerlander R, Zwahlen M. Hepatitis C in a sample of pregnant women in Switzerland: seroprevalence and socio-demographic factors. Swiss Med Wkly 2007; 137: 2732.
  • 345
    Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 2002; 14: 2534.
  • 346
    Negro F. Divisions of Clinical Pathology and of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland. Newly diagnosed case data from the Swiss Federal Office of Public Health. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 5 November 2010.
  • 347
    Swiss Federal Statistical Office. The population of Switzerland 2009, Federal Office of Statistics, Bern, 2010, Statistics of Switzerland. 01, Population, 16pp, 30 cm.
  • 348
    Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int J Infect Dis 2009; 13: 27484.
  • 349
    Turhan V, Ardic N, Eyigun CP, et al. Investigation of the genotype distribution of hepatitis C virus among Turkish population in Turkey and various European countries. Chin Med J 2005; 118: 13924.
  • 350
    Keskin F, Ciftci S, Turkoglu S, Badur S. Transmission routes for chronic hepatitis C and its relation with HCV genotypes. Turk J Gastroenterol 2010; 21: 396400.
  • 351
    Erden S, Buyukozturk S, Calangu S, et al. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Med Princ Pract 2003; 12: 1848.
  • 352
    Tozun N, Ozdogan OC, Cakaloglu Y. A nationwide prevalence study and risk factors for hepatitis A, B, C,and D infections in Turkey (abstract). Hepatology 2010; 52 (Suppl.): 697A.
  • 353
    Dursun M, Ozekinci T, Ertem M, et al. Prevalence of Hepatitis C in adults in the south-eastern region of Anatolia: a community-based study. Hepatol Res 2004; 29: 7580.
  • 354
    Yildirim B, Barut S, Bulut Y, et al. Seroprevalence of hepatitis B and C viruses in the province of Tokat in the Black Sea region of Turkey: a population-based study. Turk J Gastroenterol 2009; 20: 2730.
  • 355
    Gunduz T, Mumcuoglu I, Guray M. Evaluation of hepatitis B surface antigen, anti-hepatitis C virus and anti-human immunodeficiency virus antibodies and syphilis seropositivity in blood donors: six years' seropositivity. Int J Clin Pharmacol Res 2005; 25: 1558.
  • 356
    Afsar I, Gungor S, Sener AG, Yurtsever SG. The prevalence of HBV, HCV and HIV infections among blood donors in Izmir, Turkey. Indian J Med Microbiol 2008; 26: 2889.
  • 357
    Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006; 21: 299305.
  • 358
    Kocak N, Hepgul S, Ozbayburtlu S, et al. Trends in major transfusion-transmissible infections among blood donors over 17 years in Istanbul, Turkey. J Int Med Res 2004; 32: 6715.
  • 359
    Mutlu B, Meric M, Willke A. Seroprevalence of hepatitis B and C virus, human immunodeficiency virus and syphilis in the blood donors. Mikrobiyol Bul 2004; 38: 4458.
  • 360
    Altindis M, Yilmaz S, Dikengil T, Acemoglu H, Hosoglu S. Seroprevalence and genotyping of hepatitis B, hepatitis C and HIV among healthy population and Turkish soldiers in Northern Cyprus. World J Gastroenterol 2006; 12: 67926.
  • 361
    Sakarya S, Oncu S, Ozturk B, Oncu S. Effect of preventive applications on prevalence of hepatitis B virus and hepatitis C virus infections in West Turkey. Saudi Med J 2004; 25: 10702.
  • 362
    Demirturk N, Demirdal T, Toprak D, Altindis M, Aktepe OC. Hepatitis B and C virus in West-Central Turkey: seroprevalence in healthy individuals admitted to a university hospital for routine health checks. Turk J Gastroenterol 2006; 17: 26772.
  • 363
    Thomas DL, Mahley RW, Badur S, Palaoglu E, Quinn TC. The epidemiology of hepatitis C in Turkey. Infection 1994; 22: 4114.
  • 364
    Ozgun MT, Batukan C, Mazicioglu MM, et al. Intrauterine device use does not increase the incidence of anti-hepatitis C seropositivity among monogamous women in Turkey. Contraception 2009; 80: 2615.
  • 365
    Altinbas S, Erdogan M, Danisman N. The seroprevalences of HBs Ag and anti-HCV in pregnant women in Ankara. Arch Gynecol Obstet 2010; 281: 371.
  • 366
    Alim A, Artan MO, Baykan Z, Alim BA. Seroprevalence of hepatitis B and C viruses, HIV, and syphilis infections among engaged couples. Saudi Med J 2009; 30: 5415.
  • 367
    Maral I, Dogruman-Al F, Bakar C, et al. Hepatitis B virus and hepatitis C virus seroprevalence in the elderly living in nursing homes. J Investig Med 2009; 57: 7179.
  • 368
    Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008; 12: 23944.
  • 369
    Bozdayi AM, Aslan N, Bozdayi G, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149: 211529.
  • 370
    Abacioglu YH, Davidson F, Tuncer S, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995; 2: 297301.
  • 371
    Costella, Annastella and Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report. Health Protection Agency Centre for Infections, London, 2008.
  • 372
    Health Protection Scotland. Blood Borne Viruses and Sexually Transmitted Infections. Hepatitis C Reporting. Table 3: Persons in Scotland reported to be hepatitis C antibody positive, by age group at time of earliest positive specimen and year of earliest positive specimen, 2010, 31 December 2009, Available at http://www.documents.hps.scot.nhs.uk/bbvsti/annual-data-tables/2010/hcv-table3-2010-05.pdf (accessed 17 September 2010).
  • 373
    Hutchinson SJ, Roy KM, Wadd S, et al. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scott Med J 2006; 51: 815.
  • 374
    De Angelis D, Sweeting M, Ades A, et al. An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales. Stat Methods Med Res 2009; 18: 36179.
  • 375
    Goldberg D, Brown G, Hutchinson S, et al. Hepatitis C Action Plan for Scotland: Phase II (May 2008–March 2011). Euro Surveill 2008; 13: 12.
  • 376
    Sweeting MJ, Hope VD, Hickman M, et al. Hepatitis C infection among injecting drug users in England and Wales (1992–2006): there and back again? Am J Epidemiol 2009; 170: 35260.
  • 377
    Balogun MA, Murphy N, Nunn S, et al. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiol Infect 2009; 137: 9807.
  • 378
    Hickman M, Hope V, Coleman B, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health 2009; 31: 37482.
  • 379
    Hickman M, Hope V, Brady T, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat 2007; 14: 64552.
  • 380
    Roy KM, Hutchinson SJ, Wadd S, et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect 2007; 135: 43342.
  • 381
    Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330: 245.
  • 382
    Balogun MA, Ramsay ME, Parry JV, et al. A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection. Sex Transm Infect 2003; 79: 3016.
  • 383
    Hope VD, Judd A, Hickman M, et al. Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health 2001; 91: 3842.
  • 384
    Taylor A, Goldberg D, Hutchinson S, et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990–1996: are current harm reduction strategies working? J Infect 2000; 40: 17683.
  • 385
    Edeh J, Spalding P. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England. J Public Health Med 2000; 22: 5319.
  • 386
    Lamden KH, Kennedy N, Beeching NJ, et al. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 1998; 37: 2609.
  • 387
    Watson JP, Brind AM, Chapman CE, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 1996; 38: 26976.
  • 388
    Mutimer DJ, Harrison RF, O'Donnell KB, et al. Hepatitis C virus infection in the asymptomatic British blood donor. J Viral Hepat 1995; 2: 4753.
  • 389
    Garson JA, Clewley JP, Simmonds P, et al. Hepatitis C viraemia in United Kingdom blood donors. A multicentre study. Vox Sang 1992; 62: 21823.
  • 390
    Balogun MA, Vyse AJ, Hesketh LM, et al. Estimating hepatitis C infection acquired in England, 1986–2000. Epidemiol Infect 2009; 137: 124954.
  • 391
    Hutchinson SJ, Goldberg DJ, King M, et al. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. Gut 2004; 53: 5938.
  • 392
    Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002; 45: 21926.
  • 393
    Goldberg D, McIntyre PG, Smith R, et al. Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing. BJOG 2001; 108: 36570.
  • 394
    Thorburn D, Dundas D, McCruden EA, et al. A study of hepatitis C prevalence in healthcare workers in the West of Scotland. Gut 2001; 48: 11620.
  • 395
    Balogun MA, Ramsay ME, Parry JV, et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol Infect 2000; 125: 70512.
  • 396
    Ades AE, Parker S, Walker J, et al. HCV prevalence in pregnant women in the UK. A study of hepatitis C prevalence in healthcare workers in the West of Scotland. Epidemiol Infect 2000; 125: 399405.
  • 397
    Ward C, Tudor-Williams G, Cotzias T, et al. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 2000; 47: 27780.
  • 398
    Boxall E, Skidmore S, Evans C, Nightingale S. The prevalence of hepatitis B and C in an antenatal population of various ethnic origins. Epidemiol Infect 1994; 113: 5238.
  • 399
    Mohsen AH. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001; 48: 70713.
  • 400
    Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999; 58: 12731.
  • 401
    Saiz dlH, Marco A, Garcia-Guerrero J, Rivera A. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis 2011.
  • 402
    Chak E, Talal A, Sherman KE, Schiff E, Saab S. Hepatitis C virus infection in the United States: an estimate of true prevalence. Liver Int 2011. DOI: DOI: 10.1111/j.1478-3231.2011.02494.x.
  • 403
    Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005; 3: 3118.
  • 404
    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 38398.
  • 405
    Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 90814.
  • 406
    Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899905.
  • 407
    Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 808.
  • 408
    Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 98391.
  • 409
    van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136: 160917.
  • 410
    Jauffret-Roustide M, Emmanuelli J, Quaglia M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data – the ANRS-Coquelicot Study. Subst Use Misuse 2006; 41: 160321.
  • 411
    Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 65561.